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“If you do not expect the unexpected, you will not find it; for it is hard to be sought out, and 
difficult” 
     Heraclitus 
 
 
“There is no subject so old that something new cannot be said about it.” 
Fyodor Dostoevsky -- A Diary of a Writer (1876) 
 
 
 
To my family  

  
ABSTRACT 
Complex disease is characterized by the interplay of multiple genetic and environmental 
factors. Rheumatoid arthritis (RA) is a complex autoimmune disease with a pronounced 
genetic component, mainly due to HLA-DRB1 gene, but also a multitude of loci outside the 
HLA region. In this work we strive to contribute to the understanding of the functional 
involvement of these susceptibility loci in the pathogenesis of RA.  
This study is based on a large material of whole blood samples and peripheral blood 
mononuclear cells (PBMCs) from RA patients and matched healthy controls from Sweden.  
The main methods used in this work included probe-based genotyping and gene-expression 
assays, cell cultures, RNA-sequencing, gene-gene interaction and pathway analysis, as well 
as a plethora of common molecular genetics and bioinformatics methods. 
We investigated the role of expression of known genetic risk factors PTPN22 and PTPN2 in 
RA, with a special attention to the splicing profile of these genes. Our data indicates 
significant differences in the expression ratio of splice variants for PTPN22 in whole blood 
samples from RA patients and healthy controls. For PTPN2 we demonstrate a significant 
difference in the relative mRNA expression of' transcript TC48 in PBMCs of healthy controls 
and RA patients. Additionally, we identified new susceptibility SNPs in the PTPN2 locus: 
rs657555 and rs11080606, by addressing the interaction of PTPN2 variants with HLA-DRB1 
shared-epitope (SE) alleles in autoantibody positive RA patients in two independent cohorts. 
In this work, we also address the functional genetic role of the members of the MAP 
signaling pathway upstream of p38 and JNK – crucial enzymes in RA – with a regard to 
splicing profile and their connection to HLA-DRB1. We found a significant statistical 
interaction for rs10468473 from MAP2K4 locus with SE alleles in autoantibody-positive RA. 
Importantly, individuals heterozygous for rs10468473 demonstrated higher expression of 
total MAP2K4 mRNA in blood, compared to A-allele homozygous. We also describe a 
novel, putatively translated RNA splice form of MAP2K4, that is differentially expressed in 
peripheral blood mononuclear cells from 88 RA cases and controls, and is modulated in 
response to TNF in Jurkat cell line.   
Finally, we performed an expression analysis of multiple validated RA risk loci, and pathway 
analysis to assess functional relationship between RA susceptibility genes and predict new 
potential study candidates. New candidate molecules suggested by the pathway analysis, 
genes ERBB2 and HSPB1, as well as HLA-DRB1, were differentially expressed between RA 
patients and healthy individuals in RNA-seq data. ERBB2 expression profile was similar in 
whole blood of both treated and untreated patients compared to healthy individuals. A similar 
expression profile was replicated for ERBB2 in PBMCs in an independent material.   
In this work, we approached the task of elucidating the functional aspects of genetic 
susceptibility of RA, by integrating genetic epidemiology, transcriptomics, proteomics, cell-
models, and bioinformatics. We maintain, that such integrative approach provides the 
rationale to prioritize genes and genetic events for further functional studies. Our findings 
also outline the need to consider potential clinical significance of alternative splicing in gene 
expression studies. 
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INTRODUCTION 
 
In the following introduction, I want to provide an overview of relevant concepts in 
molecular genetics, genetic epidemiology, and rheumatoid arthritis research that served as a 
scientific context for my work. 
 
1 TRANSCRIPTION 
 
The absolute majority of living organisms, from unicellular to highly complex multicellular, 
pass the information to their offspring through DNA. DNA is a macromolecule with a 
sequence of four nucleotides which are used to store and reproduce numerous and diverse 
features of a living organism. According to the central dogma of molecular biology, DNA 
molecules need to be transcribed into RNA, which, in turn, gets translated into proteins – the 
main effectors in a cell. 
Transcription of DNA-encoded information into RNA form starts with transcription factors 
binding to the regulatory elements of the genes. This causes recruitment of the RNA 
polymerase to the transcription initiation site. To initiate the transcription, transcriptional 
enhancers cause the conformational change of RNA polymerase and allow it to unwind a part 
of a double-stranded DNA helix in order to copy one of the strands into an mRNA molecule 
(messenger RNA). During the elongation stage, RNA polymerase proceeds alongside the 
DNA strand occasionally proof-reading the synthetized transcript. The newly synthetized 
mRNA promptly undergoes non-template related modifications followed by the recruitment 
of alternative splicing machinery and mRNA maturation. The process ends by the regulated 
release of the RNA polymerase. After that, tRNAs translate mRNA from the transcript matrix 
into amino acid sequence making the ultimate functional elements (proteins).  
Canonically, a DNA motif responsible for a certain feature is called a gene and the 
collectivity of the genes define an individual species’ genome. To crack the code that makes 
us unique, Human Genome Project set out in 1990 towards the goal of annotating the 
sequences of all human genes. It culminated in a historical publication in 2004, opening the 
human genome to the public. Those years were also marked by the emergence of the 
HapMap project - a large-scale effort to catalogue the differences and similarities of the 
human genetic code between individuals and world populations, providing invaluable insight 
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into genetic variation contributing to disease, response to treatment and environmental 
factors, etc.  
However, one of the less expected revelations brought about by these monumental studies 
was the great similarity of the genetic code between individuals. Moreover, the number of 
human genes was found to be nearly identical to the one in mice, and very few protein 
families could be characterized as human-specific. These findings implied that there are 
additional levels of complexity in human genome, not necessarily explainable by the 
nucleotide sequence alone. To address this question, ENCODE (Encyclopedia of DNA 
Elements) project was launched in order to annotate all functional elements in the human 
genome by high-throughput methods. The initial result based on RNA and DNA sequencing, 
combined with chromatin immunoprecipitation (ChiP-seq) and deoxyribonuclease-based 
(DNase) footprinting demonstrated that transcription is not limited to protein-coding genes 
and is more universal than was thought before. Numerous novel transcripts (spliced and 
unspliced) were found both in protein-coding and previously considered as transcriptionally 
silent loci. This broadens both the central dogma and the classical gene definition and implies 
the existence of a complex multi-dimensional regulatory network determining the phenotype. 
It has also fast become clear that new types of non-protein coding RNAs are produced from 
relatively disregarded parts of the genome previously labeled as “gene deserts” and “junk 
DNA”. These were shown to play an important role in the embryo development as well as in 
the pathogenesis of different diseases.  
The multifaceted functionality of the transcriptome presents both exciting opportunities to 
explain the complexity of biological process, but also challenges us with a whole new level of 
complexity. 
 
1.1  RNA SPLICING MECHANISMS 
The process of mRNA splicing takes place between transcription and translation. The 
transcribed pre-mRNA still contains non-protein coding elements – introns – that need to be 
removed - “spliced-out” - to produce mature mRNA, containing only the sequence necessary 
for protein construction (Figure 1). Splicing is dependent on splice sites - the sequence 
motifs, recognized by the specialized organelle, called the spliceosome.  
Spliceosome components - small nuclear ribonucleoproteins (snRNPs) – recognize the splice 
sites, generally represented by GU sequence at the intronic 5’ end and AG sequence at the 3’ 
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end. Another motif, that guides splicing is the so-called “branch point”, located in the 
proximity of the 3’ end of the intron.  
 
 
 
 
Splicing can be influenced by other regulatory elements in the genome, such as enhancers 
and silencers. Importantly, variations in the genome, such as deletions, insertions, and single 
nucleotide polymorphisms (SNPs), can modify the structure of these elements, causing 
changes in the regulation of the transcriptome. 
 
5’#UTR# Exon#1# Exon#2# Exon#3# 3’#UTR#
TRANSCRIPTION*
DNA#
pre4mRNA#
SPLICING*
TRANSLATION*
Branch*point*
5’#UTR# Exon#1# Exon#2# Exon#3# 3’#UTR#
GU* AG*
AAAA#
mRNA#transcripts#
5’#UTR# Exon#1# Exon#2# Exon#3# 3’#UTR# AAAA#
Introns*
5’#UTR# Exon#1# Exon#3# 3’#UTR# AAAA#
Variant'1'
*
Variant'2'
V1# V2#
Protein#isoforms#
TATA*box*
Promoter*
Enchancer*
Figure 1. Schematic representation of the mRNA-maturation processes.  
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1.2 ALTERNATIVE SPLICING 
Alternative splicing is a process that makes possible production of different mRNA products 
from a single gene and ultimately – different proteins from the same gene. The phenomenon 
of alternative splicing was described almost simultaneously with the discovery of splicing 
itself (1). Generally, carrying a large number of introns that may then be utilized to achieve 
different combinations of exons in the final mRNA product may have some evolutionary 
advantage. The changes introduced to a translated protein product by alternative splicing 
could be drastic compared to single amino acid substitutions, resulting from non-synonymous 
SNPs. By regulating the functional domain composition of the final product, alternative 
splicing could affect its ability to carry out its function or form complexes with other proteins.  
As transcription starts, splicing machinery gets activated and the primary transcripts are being 
spliced as soon as the splicing sites become available (2). The process is mediated by snRNPs 
U1, U2, U4, U5, U6 and by a number of complementary proteins like U2AF65 and U2AF35. 
The catalytically active spliceosome, regulated by altered protein-protein interaction as well 
as by RNA-dependent ATPases and helicases, performs a two-step splicing reaction (5’ of the 
intron first, followed by the 3’) leading to intron excision (3, 4).  
The pre-mRNA regions at the beginning and at the end of introns contain a specific 
consensus sequence recognized by a spliceosome. The splice sites can be strong or weak 
depending on their affinity to a spliceosome determined by the sequence deviations from the 
consensus sequence. Strong sites are almost always used, whereas the usage of weak sites is 
determined by additional regulation thus providing the basis for the alternative splicing. The 
regulators of weak sites include cis-regulatory sequences (both intronic and exonic, both 
splicing enhancers and splicing silencers). Trans-regulatory factors can be universal (e.g., 
heterogeneous RNPs) or tissue-specific (NOVA, FOX, PTB, etc.)(5-8) and they can bind to 
the regulatory sequences thus providing additional level of splicing regulation. In addition, 
relative positioning of strong and weak sites, the rate of transcription (9, 10), small RNAs 
(11) also regulate this process what taken together with other factors, create vast possibilities 
for alternative splicing.  
Indeed, alternative splicing appears in eukaryotes and is more pervasive in more complex 
organisms, hinting on its protective and regulatory roles in the homeostasis (e.g., coding 
larger protein variety by a genome, extensive regulatory opportunities, protection from 
mutations, etc.) (12, 13). In humans, alternative splicing is perceived to be extremely 
common, as about 95% of all human genes are thought to have multiple isoforms (13, 14), 
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whereas the corresponding value in C.elegans is estimated to be 13-25% (15, 16). As the 
gene number is approximately similar in humans and C.elegans, it is tempting to speculate 
that alternative splicing reflects and may largely contribute to the complexity of organization. 
Notably, different tissues of the same organism may have vastly different transcript profiles, 
raising important questions about the involvement of alternative splicing in cell-
differentiation and regulation of cell-type specific functions. 
 
1.3 ALTERNATIVE SPLICING: CLINICAL SIGNIFICANCE 
Given the abundance and tight regulation of mRNA splicing, it is reasonable to assume that it 
can become deregulated. Indeed, it has been demonstrated for multiple pathological 
conditions that alternatively spliced isoforms might be of importance (reviewed in(17, 18)). 
Mutations in core splicing machinery are rare implying that they might not be compatible 
with life due to extreme importance of splicing in all cellular processes. On the other hand, 
alternatively spliced isoforms can be tolerated by an organism, but might be the cause or the 
consequence of certain diseases. Therefore, the most frequent deregulations in alternative 
splicing include mutations in the splicing sites, thus promoting generation of novel isoforms 
(with diverse functions) and impacting the isoform balance by exon skipping, using a pseudo 
splicing site or retaining the mutated intron (mutation affecting in cis)(19, 20). Also, mice 
experiments demonstrate that splicing can be altered in trans by mutations in the regulatory 
factors (e.g., mutation in NOVA-1(21)). The role of the alternatively splicing deregulation in 
autoimmunity is being constantly addressed shedding light on additional details of disease 
mechanisms (exemplified in(22-24) and in the papers included in this thesis). The 
accumulation of data on alternative splicing also suggests that it could have significant 
contribution in development of RA by acting on multiple immunological pathways. For 
instance, alternatively spliced forms of CD44, CXCL12, hRasGRP4 were shown to effect the 
invasive capacity of synovyocites, T-cell activation, and cell signaling, respectively (25-27). 
Interestingly, a separate study comparing RA and osteoarthritis patients found that naturally 
occurring IL-32γ has an alternative protein isoform IL-32β, which is a less potent 
proinflammatory mediator and thus may be a safety switch in controlling the effects of IL-
32γ and thereby decrease chronic inflammation (28). Finally, the study of Jin et al. shows that 
expression of human VEGF receptor type 1 splicing isoform in murine joints ameliorate 
collagen-induced arthritis (29).  
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Interestingly, most of the mutations causing phenotype changes are single nucleotide 
interchanges or SNPs, what gives another evidence of the importance and potential 
implications of alternative splicing. The rapidly accumulating knowledge on the involvement 
of alternative splicing in human diseases opens new therapeutic and prognostic opportunities. 
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2 GENETIC RISK 
 
2.1 MENDELIAN AND POLYGENIC DISORDERS 
Classical experiments of Gregor Mendel with Pisum sativum carried out on the backyard of 
the church during prayer-free time made a basis for the laws of inheritance and became the 
beginning of modern genetics. Currently, most of human diseases are considered to be 
genetic to some extend, even those which were believed to be due to purely environmental 
factors. Some disorders occur due to a rare genetic variant of a single gene and are, therefore, 
called single-gene disorders (e.g., sickle-cell anemia, Huntington’s disease, etc., about 4000 
disorders in total). These diseases have a classical inheritance pattern according to Mendelian 
laws and therefore, knowing the variation, it is possible to identify individuals at risk and to 
predict the occurrence of the disease.  
Most of human disorders are polygenic (complex) meaning that multiple genes as well as 
environmental factors and a lifestyle contribute to their pathogenesis. Although in some cases 
(e.g., RA, asthma, pancreatic cancer, obesity) there is a clear clustering in the families, it is 
not clear which genes are involved, what genetic variant are important and, hence, which 
individuals are at risk. Moreover, we might not always have a complete understanding of how 
much inheritance plays role in disease development. The involvement of the environmental 
factors is equally important but more difficult to detect in studies of complex diseases. 
Genotype-phenotype association studies are carried out in order to decipher genetic and 
environmental components of complex diseases for potential risk prediction and for 
development of early interventions. 
 
2.2 SINGLE NUCLEOTIDE POLYMORPHISMS (SNPs) 
SNPs are the variations of DNA sequence commonly occurring in the general population. 
Basically, a SNP is a mutation (interchange) of a single nucleotide in a particular DNA locus. 
These different nucleotide variants at a given position are referred to as different alleles, with 
the vast majority of common SNPs having just two alleles.  In 2014, the number of validated 
SNPs in humans, registered in RefSeq reached 41,735,528 (30, 31).  
SNPs in the exonic regions can be either synonymous (when the nucleotide alteration does 
not cause the change of the amino acid sequence) or non-synonymous (when a substitution in 
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the polypeptide change occurs). Non-synonymous SNPs often cause phenotype change and 
might be clearly associated with a certain disease, whereas the role of synonymous SNPs is 
usually more difficult to assess. Genetic variants in the promoter region of genes may affect 
transcription activation or interfere with silencing elements that ultimately will change 
activity of transcription. SNPs within introns may influence splicing elements and affect 
splicing mechanisms. Additionally, SNPs may influence mRNA stability, conformation of 
mRNA, change level of methylation and associated with miRNA function (32). 
The distribution of SNPs throughout the genome is not uniform. The most common regions 
of SNPs occurrence are non-translated regions (both 3’- and 5’-UTRs, as well as intergenic 
regions) where the selective pressure has not eliminated variations throughout the evolution. 
The latter were previously believed to be of no to little impact on the transcription and gene 
expression (33). However, it is becoming increasingly clear that non-translated regions may 
play a substantial regulatory role in gene expression. 
 Technology development made possible genome-wide investigation of SNPs and 
comparison of the SNP profiles between large groups of individuals.  
 
2.3 GWAS 
Sequencing of a human genome as well as annotating a human haplotype facilitated 
development and near-ubiquitous use of genome-wide studies in complex genetic diseases. 
These studies usually compare two or more groups of individuals with different phenotypes 
and aim at identification of specific genomic features associated with each of the conditions 
(case-control studies). 
Genome-wide association study (GWAS) examines common variants (SNPs) across the 
human genome. The array includes a large number of SNPs, thus allowing a hypothesis-free 
investigation of the allele frequency across the groups. To facilitate the analysis of large 
numbers of SNPs, GWAS make use of linkage disequilibrium (LD) in the genome. LD is an 
association between alleles from different loci that were inherited as a continuous sequence of 
DNA without recombination and that would not be expected to differ from their individual 
allele frequencies by random sampling of SNPs. Practically, this means that testing all known 
SNPs would be redundant, since it is possible to use a “tagging” SNP to represent an LD 
block, and to infer the associated genotypes of other SNPs in this block. This approach allows 
high cost-effectiveness of genotyping and analysis (34).  
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 The variants with higher frequency in a disease group are referred to as disease-associated 
variants and odds ratios are normally used to present effect for a certain group of individuals 
carrying genetic variant (35).  
The first large GWAS published in 2007 by Wellcome Trust Case Control Consortium 
genotyped 14,000 cases of seven common diseases (including 2,000 RA patients) and 3,000 
controls (36). This study identified novel genes involved into the pathogenesis of several 
common diseases. In case of RA, it confirmed the involvement of HLA-DRB1 and PTPN22 
variants, but also unveiled the involvement of other SNPs. For example, SNP rs11761231 
located in chromosome 7 was found to be associated with RA in women whereas carrying no 
association in men. Also, SNPs in IL2RA (rs2104286), IL2B (rs743777), as well as tumor 
necrosis factor activating protein 2 TNFAIP2 (rs2771369) were described as having 
association to RA. 
For RA, approximately 50 percent of heritability remains unexplained, and a subject of 
debate.  Although GWAS helps to get insights into previously underpinned genetic factors, 
for most of the associated variants outside of HLA-DRB1 and PTPN22 loci, the odd ratios 
are about 1.3. One of the implications may be that common genetic variants most often play 
rather small role in explaining heritability of RA and rare variants, which might play a larger 
role in the disease, are more difficult to identify. A study of 500 RA cases and 650 controls, 
discovered rare disease-associated variants in within the protein-coding portion of IL2RA, 
IL2RB and CD2 – loci, previously identified by GWAS as contributing to the risk of RA (37). 
A recent report indicates an enrichment for rare/low-frequency variants associated with RA in 
the loci responsible for mitochondria respiratory chain-related proteins, providing a link 
between reactive oxygen species and RA pathogenesis (38). Conversely, other studies of rare 
variance in autoimmune disease suggest that unexplained heritability for common 
autoimmune diseases may be a result of multiple common-variant loci of weak effect, rather 
then the rare coding-region variant portion of the allelic spectrum (39, 40). In order to address 
these issues, on one hand, the cohort sizes were increased, and, on the other hand, a more 
carefully chosen material was genotyped for a smaller subset of SNPs. However, even very 
significant and carefully controlled for confounders associations only imply the involvement 
of a given SNP into a disease, but functional studies are needed to investigate the biological 
mechanisms behind the associations. 
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2.4 GENE-GENE AND GENE-ENVIRONMENT INTERACTION 
In complex diseases, the interactions between genes and environment play a definitive role. 
Naturally, the disease association of SNPs from different loci does not provide evidence of 
gene-gene interaction. However, many methods for calculating gene-gene interaction exist, 
(e.g. additive and multiplicative interaction, multifactor dimensionality reduction, genetic 
vectors, and network biology approaches) that could directly utilize genotype information 
from GWAS studies. If the risk of developing a condition in a carrier of both susceptibility 
genotypes (as defined by a relevant dominance model) is significantly higher than a 
combination of their individual risk effects would imply, we can assume interaction between 
the two (41). This is referred to as the additive model of interaction. The percentage of the 
additional risk that cannot be explained by the sum of individual risks can be attributed to 
interaction effect size (attributable proportion of risk). The calculation relies on the logistic 
regression model that includes three groups: individuals carrying both genetic risk factors and 
those, who carry either one of the two (while the unexposed group is assigned the baseline 
risk of 1) (42). The relative excessive risk due to interaction (RERI) is defined as: 
RERI=RR11 – RR10 – RR01+1; 
Where RR11 is the relative risk in a group, exposed to both risk factors, while RR10 and  RR11 
represent relative risk in groups exposed to either risk factor 1 or 2. The attributable 
proportion (AP) is then defined as: 
AP= RERI/ RR11 
The development of high-throughput computational-based methods around this approach 
allows for pairwise calculation of interactions between large numbers of genetic risk factors 
in GWAS data (43, 44).  
Notably, approaches based on multifactor dimensionality reduction (MDR) (45, 46) have 
seen an increase in usage for assessment of gene-gene and gene-environment interactions 
(46). 
A classification of multi-locus genotypes into high-risk and low-risk classes makes it possible 
to reduce the dimensionality of genomic risk predictors to 1. The result modifies the 
contingency table in a way that facilitated the computation of statistics. The multiple 
modifications of the MDR have been used for resolving gene-gene interaction between 
specific genes in several disorders. In its current state, MDR-based interaction analysis can be 
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extremely taxing computationally, when employed on a whole-genome scale, warranting an 
optimization of the existing algorithms (47). 
Although, interaction analysis has proven to be a useful tool in assessing potential functional 
connecting in existing GWAS data, it is still not representative of the underlying biology, and 
extensive functional studies are warranted to elucidate the statistical connection (48). 
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3 RHEUMATOID ARTHRITIS 
 
Rheumatoid arthritis (RA) is a debilitating common complex autoimmune disease 
characterized by persistent inflammation of the joint, resulting in gradual erosion of the 
synovial tissue by host immune cells, leading to pain and dysfunction. It is a systemic 
disease, and can affect any joint in the body. Characteristically for autoimmunity in general, 
the disease pathogenesis is propagated by the host adaptive immune system. However, the 
factor that initially tips the host immune system out of balance is still unresolved. Several 
genetic and environmental factors have been described to contribute to susceptibility, making 
RA a disease with complex etiology.  
 
3.1 CLINICAL MANIFESTATION OF RA 
RA is a complex disease which includes both joint-specific and more general systemic 
symptoms. Joint-specific manifestations include swelling, pain, morning stiffness (which 
lasts for more than 2h) and limited motion in the joint. In principal, RA might affect any of 
the joints in the body, but smaller joints are usually more frequently affected. The long-
lasting morning stiffness is a special characteristic of RA which allows clinicians to suspect 
that the patient presents with RA rather than other arthritic diseases (for instance, 
osteoarthritis has similar symptoms with regards to pain and swelling, but prolonged morning 
stiffness is not usually present) (49). American College of Rheumatology first developed and 
later reconsidered the score-based algorithm for the diagnosis of RA. Below the clinical 
parameters for the diagnostics of RA are presented according to 2010 ACR-EULAR 
classification criteria (50). Importantly, this update introduced serological tests for anti-
citrullinated peptide antibodies (ACPA) and rheumatoid factor (RF) as an integral part of 
differential diagnosis for RA. 
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To be diagnosed with RA, a patient should have a score of ≥ 6/10. The patients with the 
lower score or with borderline cases should be followed-up, since the criteria might be 
fulfilled as the disease progresses.  
More general symptoms of RA include fatigue/loss of energy, low fever, loss of appetite, 
firm nodules growing underneath the skin. Although not necessary for the diagnosis, these 
symptoms greatly contribute to the debilitating nature of RA. 
 
3.2 PATHOGENESIS 
Although our knowledge about RA has greatly advanced during the last thirty years, the 
trigger of the disease remains unknown. The pathogenesis of the disease, however, is better 
understood which made possible the development of the symptomatic therapy. 
Table 1. The 2010 ACR-EULAR classification criteria for RA. Large joints refer to 
shoulders, elbows, hips, knees, and ankles. The duration of the symptoms is self-
reported by patients. RF - rheumatoid factor; CRP - C-reactive protein; ESR - 
erythrocyte sedimentation rate. 
Target'Population
1.#patients,#having#at#least#1#joint#with#definite#clinical#synovitis#(swelling)
2.#synovitis#cannot#be#explaind#by#another#disease
Classification#criteria#for#RA
A.'Joint'involvement'
1#large#joint 0
2A10#large#joints 1
1A3#small#joints#(with#or#without#invovement#of#large#joints) 2
4A10#small#joints#(with#or#without#invovement#of#large#joints) 3
>10#joints#(at#least#1#small#joint) 5
Serology'(at'least'1'test'result'is'needed'for'classification)
Negative#RF#and #negative#ACPA 0
LowApositive#RF#or#lowApositive#ACPA 2
HighApositive#RF#or#highApositive#ACPA 3
C.'Acute'phase'reactants'(at'least'1'test'is'needed'for'classification)
Normal#CRP#and #normal#ESR 0
Abnormal#CRP&or#abnormal#ESR 1
D.'Duration'of'symptoms
<6#weeks 0
≥6#weeks 1
Score	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It is believed that before the disease onset, an individual is exposed to certain environmental 
factors which “prepare the ground” for further events leading to RA (described in more detail 
in the corresponding section of this thesis). These environmental factors are not specific for 
RA and are normally managed well by the general population. However, some individuals 
are more predisposed to the development of autoimmunity due to their genetic background 
(MHC class II genes, PTPN22, polymorphisms in cytokine promoters and other yet 
unidentified genes; described in the section “Genetic factors of RA”). Even long before the 
symptoms occur, RF and ACPA can be detected in the blood as evidence for autoimmune 
reactions (51, 52). 
For the reasons which are not yet completely understood, the synovial tissue is primarily 
targeted in RA. The potential antigens include citrullinated peptides, immunoglobulins, heat-
shock proteins as well as cartilage antigens (e.g., type II collagen, aggrecan, proteoglycans, 
etc.), however, there is no evidence of a specific rheumatoid antigen. Antigens are processed 
by dendritic cells, which then present peptides to naïve T-cells in the local and central 
lymphoid organs. In turn, T-cells activate B-cells to produce pathogenic antibodies and/or to 
move to the synovial tissue and engage into a complex interaction network with other cells 
present on the site. Once this happens, the antigen is not necessary anymore and the cells 
cross-activate each other through non-specific cell-to-cell communication mechanisms (53). 
This leads to the beginning of a destructive process involving pro-inflammatory cytokine 
production, cartilage destruction by matrix metalloproteinases and increased levels of reactive 
oxygen and nitrogen. The organism’s inflammation-limiting capacity is not capable to 
dampen this process through the production of suppressive cytokines. Further, synovial 
intimal hyperplasia occurs which is associated with deficient apoptosis, deregulation of a key 
tumor suppressor p53 and even upregulation of pro-angiogenic factors (e.g. HIF-1α, VEGF, 
soluble VCAM) (54). 
Clearly, multiple cellular types of the synovium participate in the pathogenesis of RA. These 
include macrophage-like type A synoviocytes, fibroblast-like type B synoviocytes (the 
absolute number of both these subpopulations is increased in RA, skewed towards type A), 
highly activated macrophages, lymphocytes which can actively infiltrate or form aggregates, 
CD4+ T-cells which have memory phenotype, antigen-induced and antibody-producing 
synovial B-cells, mast cells producing large number of mediators of inflammation, dendritic 
cells, etc (55). Apart from that, it has been demonstrated that mesenchymal cells from the 
bone marrow can migrate and reside in the synovial tissue, interact with other cells and 
contribute to the development of synovitis (56).  
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Also, peripheral lymphocytes of RA patients are notably different from those of healthy 
individuals. Firstly, the counts of CD4+ helper T-cells are drastically increased in circulation 
(whereas CD8+ T-cells are accordingly decreased), and the cells show the features of 
activation (57). B-cells capable of producing RF are also significantly elevated in the 
peripheral blood and synovial tissue of RA patients (58, 59). Whether these cells escape from 
the synovial site of inflammation or they are produced in the lymphoid organs in response to 
antigens is not clear, but it is recognized that the peripheral blood profile is different from that 
of healthy individuals (60). These changes make it possible to use peripheral blood of RA 
patients for diagnostic, as well as prognostic studies (61). 
The repertoire of the cells considered for the development and progression of RA is wide and 
new probable players are continuously added to the list. The description provided here is far 
from being complete, but identifies some key cell types. 
 
3.3 CYTOKINES IN RA 
Cytokines are small proteins allowing communication between different cell types of the 
immune system. Each cell type is capable of producing a certain set of cytokines which are 
regulated by a certain set of transcription factors. Since multiple types of immune cells are 
implicated into the pathogenesis of RA, abnormal cytokine production is also a marked 
characteristic of RA. Th1 cells mainly produce IFNγ which is a potent inducer of MHC class 
II. IL-2, another Th1-produced cytokines, serves as a growth factor for T-cells. Apart from 
that, TNF, GM-CSF and IL-6 can be produced by both Th1 and Th2 cells (controlled by 
STAT4 in the former case and by GATA-3 and STAT6 transcription factors in the latter case) 
(62). Th17 cells produce different isoforms of IL-17 under control of the transcription factor 
STAT3 (63). The main part of massive cytokine burden comes from activated macrophages 
and fibroblasts, which produce a wide range of cytokines (e.g., IL-1, IL-6, IL-10, IL-15, IL-
18, TNF, RANKL, etc).    
TNF has been defined as one of the key pro-inflammatory cytokines in RA (64). It can be 
detected both in the synovial tissue and in the serum of RA patients which led to the 
development of targeted anti-TNF therapy (65). It is a pleiotropic cytokine produced mainly 
by monocytes in a membrane-bound form and being cleaved by a specific MMP. Through 
binding to a set of own receptors, TNF is able to regulate the production of other pro-
inflammatory cytokines, as well as to increase the expression of adhesion molecules and 
MMPs in synoviocytes (66). The success of anti-TNF therapy underlines its crucial role in 
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RA and, on the other hand, points to the heterogeneity of the disease, as  ⅓ of RA patients do 
not respond to the therapy (67). Also, continuous therapy is needed to reach a clinically 
noticeable improvement which suggests that TNF is an intermediate, although crucial, player 
in the pathogenesis of RA, and the main players are yet to be determined. 
 
3.4 CURRENT TREATMENT STRATEGIES 
RA is a chronic disease, for which there is currently no cure. Partially, the reason for that is 
that our knowledge about the causative agent for RA still limited and therefore, it cannot be 
targeted. Given that, the current treatment aims at symptom relieve and slowing down the 
disease progression. The early stage of RA (usually 3 months to 2 years after the first 
symptoms appear) is considered to be “a window of opportunity” meaning that application of 
the therapy on this stage can halt or significantly slow down the disease progression (but not 
to revert the disease).  
Disease-modifying anti-rheumatic drugs (DMARDs) are a group of otherwise unrelated 
classes of medicines which are normally prescribed as soon as RA is diagnosed. The 
mechanisms of their action are not always completely understood, but they all exhibit anti-
inflammatory effects. Methotrexate is often a drug of choice for the initial treatment, but 
other drugs (e.g., leflunomide, azathioprine, sulfasalazine etc.) are also available and can be 
combined to reach the clinical effect and to suit the individual toleration. The latter is of 
extreme importance due to usually a life-long prescription of DMARDs. DMARDs can be 
safely combined with NSAIDs, that provide analgesic effect and can be effective in reducing 
stiffness (68). Profound inflammation is often treated with short courses of cortisone and 
other cortisone-like medicines (69)  
If DMARDs do not suit the patient or stop working eventually, biological therapies are 
commonly applied. The first biological therapeutics developed for the use in RA were TNF 
receptor and anti-TNF antibodies which revolutionized the rheumatology field (70). Other 
biological therapies (IL6 blockers, removers of B- and T-cells) are also available (71, 72). 
Also, a number of clinical trials for other drugs (both biologicals and non-biologicals) are 
currently under way (73-75). All of them are directed towards dampening inflammation.  
If medications fail to help a patient, joint surgery of different level of invasiveness is being 
applied. 
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To summarize, a number of relatively effective medications are available for the treatment of 
RA patients. However, medication withdrawal after the remission has not been proven 
beneficial for the patients, making RA a life-long condition that requires constant and 
expensive management.  Therefore, search for causative agents must be intensified to develop 
a potentially curative treatment. 
  
3.5 GENETIC RISK FACTORS FOR RA 
The results from a number of twin studies characterize RA as a disease with relatively high 
heritability of around 60%, hinting at a pronounced genetic component of the disease (76), 
however other studies give lower estimates, especially for ACPA-negative RA (77).  A 
number of known genetic susceptibility loci for RA has greatly increased with the advance of 
genome-wide association studies. However, the most considerable risk of RA development 
stems from HLA-DRB1 locus. The higher prevalence of RA among females suggests that 
gender-related genes may also play a role in susceptibility. Close to 50% of RA heritability 
cannot be currently explained by known genetic associations (77). 
Below some of the common genes associated with the RA risk are described in more detail. 
HLA-DRB1 
HLA genes code for major histocompatibility complex molecules (MHC) which play an 
important role in the immune system of vertebrates. There are two distinct classes of HLA (I 
and II), each of these coded by specific gene regions located in chromosome 6. The function 
of HLA class I and HLA class II is to present the processed antigens to the immune cells and 
to modulate the interaction between the immune cells. Additionally, the area between HLA 
class I and II, which is sometimes denoted as HLA class III, represents a heterogeneous set of 
molecules involved into immune responses. 
In the context of autoimmunity and RA, the role of HLA class II is one of the most influential 
findings to date. It was recognized before genome-wide arrays became available and still 
remains the strongest genetic factor in RA (78). The region is comprised of HLA-DR, HLA-
DP and HLA-DQ loci, encoding α- and β-chains of HLA class II molecules which are 
expressed as heterodimers on the antigen-presenting cells. When a naïve T-cell encounters an 
antigen coupled to HLA, its TCR is primed by a peptide-HLA II complex and a cell gets 
polarized according to the cellular context. Generally, HLA class II were found to be 
upregulated in the synovial tissue of RA patients. Initially, genotyping and later sequencing 
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of HLA-DRB1 (encoding polymorphic β-chain of the DR molecule) indicated that different 
variants of this molecule differ between populations. This led to proposing a hypothesis of 
shared epitope (SE), which points out the importance of a highly conserved region in the 
amino acid residues 70-74 of the third hypervariable β-chain (i.e., 
QKRAA/QRRAA/RRRAA) (79). However, it was later demonstrated that SE is mainly 
associated with ACPA-positive RA implying a role of SE in the presentation of citrullinated 
peptides. Mechanistically, crystallographic analysis showed that the risk-associated variant 
creates a positively charged groove that binds negatively charged citrullinated antigens. 
Conversely, the non-associated variant makes a negatively charged pocket of DRB1, thus 
preventing the interaction with the citrullinated peptides (80).  
Although being in the strongest association, HLA-DRB1/SE explains only a fraction of 
ACPA-positive RA cases. Additionally, HLA-DRB1 locus may not be the only one 
responsible for susceptibility effects. A study of 1,352 patients with RA and 922 healthy 
individuals demonstrated that DRB1*13 allele plays a dual role in the development of RA, by 
protecting against ACPA-positive RA but, in combination with DRB1*03, increasing the risk 
of ACPA-negative RA. (81) 
Later studies demonstrated that the amino acid valine at position 11 at HLA-DRB1 gene has 
highest association with RA, while amino acids lysine and alanine within SE sequence 
(positions 71 and 74) have an independent effect on risk (82). 
The relative impact of each mechanism and the involvement of other genes are still being 
investigated.  
PTPN22 
Being the largest risk factor for RA, outside of HLA region, a SNP in PTPN22 (a gene 
coding for lymphoid phosphotase LYP) is also an important contributor to pathogenesis in 
other immune diseases (83). A single SNP - R620W (rs2476601) was initially discovered to 
be in association with type 1 diabetes (T1D), systemic lupus erythematosus, and later as a risk 
genotype in multiple autoimmune diseases (reviewed in (84).  
Structurally, the disease genotype is a substitution of arginine (R) to tryptophan (W) in the 
non-catalytic part of LYP. The current understanding of the functional impact of R620W is 
still incomplete, with some reports of gain of function, as well as a loss of function, in 
lymphocytes (85). Mouse models demonstrated an increase in germinal center activity and 
serum levels of immunoglobulins in both PTPN22 knockouts and mice expressing the risk 
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allele (86). Increased germinal center activity could potentially further exacerbate the 
autoimmune condition driven by other genetic loci. Additionally, the presence of the R620W 
allele could influence the substrate specificity of LYP, possibly resulting in a loss of function 
with some substrates and a gain of function with others. 
PTPN2 
PTPN2 is a comparatively new entry in the list of genetic risk factors for RA. Genetic 
variants in this gene have been reported to be associated with RA, juvenile idiopathic 
arthritis, and Crohn’s disease in several studies (36). Intronic PTPN2 SNP rs16939895 has 
been shown to be associated with Crohn’s disease and celiac disease (87).  
PTPN2 gene codes for an enzyme tyrosine-protein phosphatase non-receptor type 2, a 
member of the protein tyrosine kinases (PTP) superfamily. Two alternatively spliced 
isoforms were identified: TC45 (which contains a nuclear localization signal) and TC48 
(located primarily in the endoplasmic reticulum) and the existence of several more spliced 
isoforms was predicted (88). The isoforms share the crucial catalytic domain, but the TC45 
lacks C-terminal domain that was found to be inhibitory for the phosphatase activity. TC45 
has been demonstrated to have various targets involved into the pathogenesis of RA (JAKs, 
STAT1, STAT4, STAT3, p42/44, ERK) (89-91). PTPN2 is assumed to participate in the 
regulation of TNF as well as IFNγ signaling hinting on its role in autoimmunity. Several 
studies addressed this change of function and have indeed found evidences for immune 
regulatory effects, suggesting that cells with the disease associated allele may have a gain of 
function for PTPN2 resulting in a stronger negative regulation of T cell activation and B cell 
activation (92, 93). However, the exact mechanisms by which PTPN2 influences RA 
development are not completely understood.  
PADI4 
PADI4 represents the peptidyl argenine deaminase enzyme, responsible for the 
posttranslational modification of argenine into citruline. Initially discovered as an RA 
susceptibility locus in Asian population (94), PADI4 has a stronger effect on RA risk in the 
individuals of Asian, rather than European ethnicity (95). It is speculated, that gene-
environment interaction (namely, the much higher prevalence of smoking in East Asian 
males, compared to Europeans) could account for inter-population discrepancies in effect size 
(96). 
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TNFAIP3 
The tumor necrosis factor-α-induced protein 3 (TNFAIP3) locus has been found associated 
with the increase in risk for both RA (97, 98) and systemic lupus erythematosus (99, 100). 
One of the known functional variants is a missense substitution of phenylalanine with 
cysteine at amino acid position 127, impairing function of A20 - the ubiquitin-editing enzyme 
(100). The other associated variant is a TT>A polymorphic dinucleotide located downstream 
of the TNFAIP3 promoter that results in reduced TNFAIP3 expression (101). A20 is known 
to be inactivated by somatic mutations in B-lineage lymphomas (102), and similar events 
have been observed for other genes associated with lymphomas, such as REL, FCRL3, and 
DDX6, in which common variants are associated with RA (103), possibly pointing out the 
difference in underlying pathogenic mechanisms.  
STAT4 
The signal transducer and activator of transcription 4 (STAT4) was identified as a 
susceptibility locus for RA, SLE and Sjogren’s syndrome (104, 105). The risk allele genotype 
is associated with the overexpression of STAT4, suggesting that the product of the gene may 
contribute to autoimmunity (106). It is possible that the major role of STAT4 in type I 
interferon signaling, as well as in differentiation of  T-helper cells underlie the association of 
this locus with several autoimmune diseases.  
MAP2K4 
In our work, MAP2K4 (mitogen-activated protein kinase kinase 4) was discovered as an RA 
susceptibility locus in interaction with HLA-DRB1 (107). MAPKs have attracted 
considerable attention as potential targets for autoimmunity because they can alter the 
production of key inflammatory mediators (108). There are three major families of 
MAPKs—namely, p38, extracellular-regulated protein kinase (ERK) and c-Jun N-terminal 
kinase (JNK). MAPK activation is mediated by upstream MAPK kinases (MKKs or 
MAP2Ks), which in turn, are activated by MKK kinases (MKKK or MAP3K) (109). p38 
activation and phosphorylation is regulated by two upstream kinases, MKK3, MKK6 and, 
reportedly, MAP2K4, which are all phosphorylated by multiple upstream MAP3Ks. 
MAP2K4 (in tandem with MKK7) is also involved in co-activation of JNK, which has a 
regulatory effect on the expression of HLA class II genes and CIITA, directly related to 
antigen presentation (110). The p38-mediated signaling cascade culminates in increased 
expression of proinflammatory molecules like TNF, IL-6, IL-1, cyclo-oxygenase 2 (COX-2) 
and metalloproteinases (MMPs) (111). 
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Being among the major regulators of proliferation and differentiation of T- and B- cells, JNK 
and p38 were considered to be very promising drug targets for rheumatoid arthritis. However, 
clinical trials of direct inhibitors were largely disappointing with undesirable side effects. It 
has since been proposed, that targeting molecules involved in activation and regulation up-
stream of JNK and p38, like MAP2K4, may allow for fine regulation of the activity of these 
kinases (112). 
 
3.6 ENVIRONMENTAL FACTORS  
Most of the known environmental factors for RA are described for the ACPA-positive subset 
of the disease. 
ACPA-negative RA patients are a much smaller group, which makes it less studied. 
Additionally, the two major subgroups of RA differ profoundly in the gene expression 
profiles as well as in the possible influence of certain environmental factors(113). 
Multiple epidemiological studies indicate that smoking is an environmental factor best 
associated with ACPA-positive RA(114-116). By controlling genetic background in twin 
studies, it was demonstrated that the smoker was much more prone to develop RA than the 
non-smoker. The risk of developing RA has been described to have a linear relationship with 
the intensity of cigarette use, being twice as high for a heavy smoker compared to a non-
smoker. Interestingly, the risk of developing RA can remain elevated for decades after 
secession of smoking(117). 
 Another well-confirmed environmental factor responsible for higher RA risk is chronic 
exposure to crystalline silica (118), which can occur in many industrial settings, such as 
mining, construction work and electronics production. Similarly to smoking, long-term 
exposure to silica occurs primarily through inhalation, and can contribute to a two-fold 
increase in risk, after accounting for the confounding effects of smoking (119). 
Among other occupational exposures that could contribute to the development of RA, 
extended contact with mineral oil was found to be associated with disease susceptibility in a 
study on Scandinavian population (120). 
Alcohol consumption was shown to be associated with the protection from ACPA-positive 
RA in some epidemiological studies (121, 122). Protective effect of alcohol was found to be 
dose dependent, with individuals having 5 or more drinks per week being 40-50% less likely 
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to develop RA, compared to non-drinkers or individuals with low alcohol consumption. 
Alcohol administration was also correlated negatively with the disease severity in animal 
models of arthritis.  
Some dietary aspects are suspected to be an influence in RA, since fasting and vegetarian diet 
were shown to decrease disease activity. However, some of the larger and more recent studies 
struggled to find an influence of consumed amounts of protein, poultry, red meat, and fish on 
RA risk, while others reported that a diet containing fatty fish could be protective, as was 
vitamin D intake (123). 
Additionally, some data also point out the protective role of hormone replacement therapy in 
the post-menopausal period, suggesting the effect of estrogen (124). On the other hand, usage 
of oral contraceptives was not convincingly associated with RA onset or development.  
Other possible factors include weight at birth, breastfeeding, occupation, socioeconomic 
status, region of birth, etc., however the exact mechanism of their influence remains yet to be 
determined. 
 
3.7 GENE-GENE AND GENE-ENVIRONMENT INTERACTION IN RA 
Several notable interactions between RA risk factors have been identified. Smoking has been 
well-established as a major environmental factor for RA, leading to a number of studies 
addressing smoking as factor in gene-environment interaction studies of RA (125-127). This 
led to a discovery of a pronounced interaction between smoking habits and the number of 
carried HLA-DRB1 alleles in regard to RA risk. Specifically, carriers of two HLA-DRB1 SE 
alleles, had a 21-fold increase (and a 40-fold increase in case of heavy smoking) in risk of 
developing ACPA-positive RA, compared to non-smokers, who do not have HLA-DRB1 risk 
alleles. Considering that individually, SE alleles and smoking account only for 5-fold and 2-
fold increases in risk, respectively, it is very likely that gene-environment interaction plays a 
major role in RA etiology (128).   
The gene-gene interaction between the 2 major genetic risk factors in RA – HLA-DRB1 SE 
and PTPN22 polymorphism R620W – was confirmed in three independent study materials 
from North America, the Netherlands, and Sweden (129, 130). Individuals, carrying at least 
one copy of each risk genotype were almost 10-fold more susceptible to RA compared to 
individuals, carrying none of the susceptible genotypes. Notably, in the absence of HLA-
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DRB1 alleles, PTPN22 risk allele alone did not produce an increase in risk for ACPA-
positive RA in carriers. 
Finally, it was found that there is an environment-environment interaction between exposure 
to silica and smoking, leading to higher RA susceptibility (131). The risk of developing RA, 
is almost 8 times higher in silica exposed current smokers, while in non-smoking individuals, 
exposed to silica, it is around twice the risk of the unexposed. 
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4 CONCLUSIONS OF INTRODUCTION 
 
This introduction served to convey the following points to provide context for my work: 
Alternative splicing is an important and often overlooked mechanism that is an integral part 
in the regulation of many biological processes on both mRNA and protein level. There is 
multiple evidence that alternative splicing may consequently also play an important role in 
the development of human diseases.  
GWA studies have provided an invaluable insight into the genetic component of various 
diseases by addressing disease-associated variants across individuals and populations. 
However, the functional implications of these associations are often insufficiently 
understood. 
Studies of gene-gene and gene-environment interactions can greatly expand on the 
application of GWAS data in pinpointing functionally relevant candidate genes and signaling 
pathways. 
RA is common autoimmune disease with complex etiology and debilitating inflammation of 
the joints. The disease is sub-divided by its serological profile, determined by the presence of 
autoantibodies to citrullinated peptides. A host of environmental and genetic factors play a 
role in the development of the disease. 
Gene-gene and gene-environment interaction can potentially account for unexplained 
heritability and population effect-size differences of known susceptibility loci in RA. 
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5 STUDY DESIGN 
5.1 AIMS 
The general aim of this thesis was to bridge genetic association and functional processes 
behind RA pathogenesis, and to better understand functional role, which the genetic 
component plays in the development of the disease. While we specifically look at 
susceptibility loci outside the well-established HLA-DRB1, we strive to understand the 
cumulative effects and possible interplay of the latter with the former. We also maintain that 
addressing the balance of alternative mRNA products provides a more telling picture than 
bulk gene expression.   
More specifically, in paper I we aimed to address the effect of the risk-associated 
polymorphism in PTPN22 on the expression of this gene, with regard to its known alternative 
mRNA isoforms. In paper II we continue to apply a similar approach to another member of 
the phosphatase family, PTPN2, which is also characterized by a polymorphism with a strong 
association to RA, while also addressing its potential interaction with HLA-DRB1. In paper 
III we explore the possibility of interaction of the members of the MAPK pathway with SE, 
and detailing clinical relevance of splicing in the gene MAP2K4. In paper IV, using RNA-seq 
data and pathway analysis, we attempt to establish new candidates for molecular studies of 
RA pathogenesis. 
 
5.2 METHODS  
5.2.1 Patient cohorts 
In this work, the population-based EIRA (Swedish Epidemiological Investigation of 
Rheumatoid Arthritis) cohort was included with overall 2010 RA cases and 2280 control 
individuals. All cases met the American College of Rheumatology (ACR) 1987 criteria for 
RA(50). This cohort was built up from the incident cases of RA documented in the middle 
region of Sweden starting from year 1996. To each patient in the cohort, 1-2 healthy control 
individuals were matched based on gender, age and the residence area. All individuals 
participating in the study filled in a comprehensive questionnaire on their background, health 
issues, life style, etc (132).  
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The North American Rheumatoid Arthritis Consortium (NARAC) study comprised 873 
ACPA positive RA cases and 1196 controls. The NARAC study included ACPA positive RA 
patients of self-reported white ancestry that were randomly drawn from four different groups 
of samples. All cases met the ACR 1987 criteria for RA(50). Control subjects from the New 
York Cancer Project were enrolled during a 2-year period by means of general advertising 
and point-of-service solicitation, as described previously(133). Information on phenotypic 
and genotypic data from NARAC was used by courtesy of Prof. Peter Gregersen from 
Feinstein Institute for Medical Research and Dr. Robert Plenge from Broad Institute. 
Several sample materials were used for expression studies:  
The RNA expression experiments utilized PBMC-samples from 44 RA patients and 44 
controls, and an independent source of whole blood samples from 80 RA patients and 80 
controls from the Swedish population; controls were selected with consideration to gender, 
age and ethnicity for the patient group. RA patients were selected at the Rheumatology Clinic 
at Karolinska University Hospital on two occasions, and all correspond to ACR 1987 criteria 
for RA. Information about anti-citrullinated protein antibody (ACPA) status, smoking habits 
and medication (for RA patients) was obtained from medical records.  
In paper I, two additional independent cohort were used, (II) including 47 RA patients and 19 
controls from Sweden, and 48 RA patients and 48 controls from the US respectively; PBMCs 
from 60 multiple sclerosis (MS) patients from the same geographical area as cohorts I and II 
were also used in the study (Cohort IV).  
RNA-seq experiments in paper IV were performed on whole-blood RNA samples from 12 
healthy female controls, 6 untreated (“naïve”) female RA patients, and 6 female RA patients 
receiving standard treatment with methotrexate. The replication cohort consisted of PBMC 
samples from an independent material of 48 untreated female RA patients, methotrexate 
treated female RA patients, and 35 healthy female controls. 
Informed consent was obtained from all participants in all cohorts, in compliance with the 
latest version of the Helsinki Declaration. Regional ethical committees at all sites have 
approved the study. 
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5.2.2 Cell culture models 
To address the effect of methotrexate on the expression of PTPN22 isoforms in Paper I, we 
used Jurkat (immortalized T-lymphocytes) and Daudi (B-lymphoblasts) cell lines. To assess 
the expression of PTPN22 in different cellular systems, the following cell lines were used in 
addition to the above mentioned: Raji (lymphoblast-like B-lymphocytes), U266, RPMI 8226 
(both are multiple myeloma cell lines) and HEK293 (a transformed human embryonic kidney 
cell line). 
In Paper III the following cell lines were used to address the expression of MAP2K4 
isoforms: Jurkat, Raji and U937 (a monocyte cell line). Also, HEK293 cell line was used in 
this study for overexpression of alternatively spliced isoforms of MAP2K4. 
All the cell lines were maintained according to the recommendations of ATCC.  
 
5.2.3 Transcript discovery by polymerase-chain reaction (PCR) 
To investigate the expression of novel alternatively spliced products, we first amplified the 
canonical isoforms using conventional PCR. PCR allows fast and profound amplification of a 
gene product existing in a cell in a very few copies into the quantities which are possible to 
visualize. It allowed us to assess whether using the primers for the canonical isoforms we 
were able to amplify other isoforms as well. After the preliminary assessment of potential 
transcript diversity, PCR product was inserted into a plasmid and transfected into a bacterial 
system. Screening by electrophoresis was used to identify transformants of interest, and the 
sequence of prospective alternative transcripts was confirmed by sequencing. The sequences 
were compared to the annotated isoforms with the use of bioinformatics tools. 
 
5.2.4 Gene expression analysis 
As a proxy of the gene expression, the abundance of the transcript (number of mRNA copies) 
is commonly measured. A modification of the conventional PCR described above has been 
made to allow for simultaneous amplification and quantification of the transcript (134). 
cDNA (complementary DNA) is first being generated from RNA using a viral RNA-
dependent DNA polymerase (reverse transcriptase). Thereafter, there are two main ways to 
quantify the amount of a specific cDNA region, but both of them rely on using fluorophores 
and translation fluorescence intensity into relative quantities of cDNA (and hence, mRNA). 
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We used the variety of qRT-PCR based on a pair of template-specific primers and a template-
specific probe coupled to a fluorescent reporter (Taqman assay). The probe-based design of 
TaqMan assays allowed for more precise targeting of specific exon-junctions, making it 
possible to quantify alternative transcripts from a single locus. In all the papers of this thesis, 
we used relative quantification method which relies on detecting the difference in the 
expression level between groups of samples (e.g., from patients and controls), with 
normalization against the expression of the reference gene within each group. 
 
5.2.5 Gene-gene interaction analysis 
In our work, we used additive model of interaction. To assess genetic interaction, relative 
excessive risk (departure from additivity) was calculated for the group of individuals, 
carrying both prospective risk markers, and represented as the attributable proportion of risk 
due to interaction (AP) with 95% CI. All SNPs were tested for interaction with SE alleles 
using the binary dominant/recessive model. Additional stratification criteria could be applied 
(e.g. presence of ACPA-autoantibodies). Gender was treated as a potential confounder. When 
testing multiple SNPs for interaction, we applied Bonferroni correction to p-values for AP in 
order to circumvent the multiple comparisons problem. 
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6 RESULTS 
 
6.1 PAPER I: THE BALANCE OF EXPRESSION OF PTPN22 SPLICE FORMS 
IN RHEUMATOID ARTHRITIS 
PTPN22 has long been known as the most important genetic risk factor in rheumatoid 
arthritis, outside of HLA locus. The PTPN22 gene encodes an 807 amino acid protein called 
lymphoid tyrosine phosphatase (LYP), which belongs to the proline-, glutamic acid-, 
serine-, and threonine-rich (PEST) group of non-receptor classical class I protein tyrosine 
phosphatases. An amino acid substitution, resulting from a SNP rs2476601, resulted in 
altered signaling in T and B cells, has been confirmed to be associated with RA in multiple 
populations. Importantly, PTPN22 is strongly implicated in a number of other autoimmune 
diseases, such as type 1 diabetes, systemic lupus erythematosus, juvenile idiopathic arthritis, 
and Graves’ disease. 
The current understanding of the functional impact of 620W is still incomplete, with some 
reports of gain of function (135, 136), as well as a loss of function (137), in lymphocytes. 
These discrepancies may be attributed to the difference in function between human PTPN22 
and its murine analogue.  
PTPN22 expresses several splice forms, but there is surprisingly little known about the 
function and regulation of these products (Figure 2). At least two of them are translated into 
proteins, LYP1 (PTPN22_v1) and LYP2 (PTPN22_v4)(138). 
To evaluate expression of the PTPN22 splice forms and their possible relation to RA, we 
measured the expression levels of PTPN22-long isoforms and the short isoform PTPN22_v4, 
relative to a ZNF592 expression in PBMC from 44 RA patients and 44 controls from 
Sweden (Cohort I). 
  
.  
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Figure 2. Exonic-intronic structure of splice forms and domain representation of PTPN22. A genomic 
illustration of PTPN22 in human chromosome 1p32. Hs00247352_m1 and Hs00249262_m1 are assay numbers 
(Applied Biosystems). The four SRC homology 3 (SH3) domains are denoted by P1 to P4 and are typically 
involved in protein-protein interaction. Known binding sites for carboxy-terminal Src kinase (Csk) and CD2- 
binding protein 1 (CD2BP1) are located in P2 and P4 (carboxy-terminal homology (CTH) domain), respectively. 
The carboxyl terminus of Lyp1 contains a consensus motif for cyclin-dependent kinase 1 (CDK1). The exonic 
and basic domain structure is deduced from Ensembl (Ensembl 64, September 2011) and UCSC Genome 
Browser (GRCh37/hg19 assembly). 
By comparing the ratio of expression, we found that the profile of PTPN22 isoform 
expression in RA cases is significantly different compared with that in controls (p = 6 × 10-9, 
Mann-Whitney U test) (Figure 3 A), which is a result of significantly higher expression of 
PTPN22-long isoforms and simultaneously slightly lower expression of PTPN22_v4 in 
patients. We found that the average expression of PTPN22 splice forms in IFNγ-stimulated 
PBMCs from the same healthy individuals and RA patients was similar for RA patients and 
controls for the ratio between PTPN22_v4 and PTPN22-long forms (Figure 3c).  
 
The HLA-DRB1 SE was found to be moderately associated with the expression of PTPN22. 
RA patients carrying two copies of the SE had moderately higher expression of both 
test with P = 0.05 as a threshold for significance with
Bonferroni correction when necessary.
Results
Differential expression of PTPN22 splice forms in PBMCs
from healthy controls and patients with RA
To evaluate expression of the PTPN22 splice forms, we
measured the expression levels of PTPN22-long isoforms
and the short isoform PTPN22_v4 (LYP2; Figure 1), rela-
tive to ZNF592 expression in PBMCs of healthy indivi-
duals and RA patients (cohort I) after 6 h of cultivation of
cells without stimulation. For both assays, we detected a
difference in average expression between patients and con-
trols. For PTPN22_v4 we saw a reduction in expression
(0.85-fold decrease, non-significant) in RA cases and for
PTPN22-long isoforms an increase in expression for RA
cases (1.20-fold increase, P = 0.006) (Table 1).
Since we used two assays to measure every sample, we
could normalize the expression data by calculating a ratio.
This reflects the balance between productions (and stabi-
lity) of these splice forms for each individual and provides
a better measure for comparing individuals by reducing
the effect that the endogenous reference may have. By
comparing the ratio of expression (Figure 2), we found
that PTPN22 expression in RA cases is significantly differ-
ent compared with that in controls (P = 6 × 10-9), which is
a result of significantly higher expression of PTPN22-long
isoforms and simultaneously slightly lower expression of
PTPN22_v4 in patients (Table 1).
To replicate our findings, we measured expression of
the PTPN22 splice forms in two independent collections
of mRNA from whole blood from 19 controls and 47
RA patients from a Swedish population (cohort II) and
48 controls and 48 RA patients from the US (cohort
III). The difference in expression was significant for the
ratio of the transcripts (P = 0.02 and P = 0.01 for
cohorts II and III, respectively) and demonstrated a
similar trend for higher expression of PTPN22-long iso-
forms in cohort II and lower expression of PTPN22_v4
in cohort III (P = 1.2 × 10-4) for patients with RA
(Table 1).
IFNg-induced expression of PTPN22 splice forms in
healthy controls and patients with RA
To facilitate a mechanistic interpretation of differential
expression of PTPN22 splice forms, we also measured
PTPN22_v4, Lyp2 
?
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SH3 dom, P3 
CTH dom, SH3 dom, P4 
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Figure 1 Exonic-intronic structure of splice forms and domain representation of PTPN22. A genomic illustration of PTPN22 in human
chromosome 1p32. Hs00247352_m1 and Hs00249262_m1 are assay numbers (Applied Biosystems). The four SRC homology 3 (SH3) domains are
denoted by P1 to P4 and are typically involved in protein-protein interaction. Known binding sites for carboxy-terminal Src kinase (Csk) and CD2-
binding protein 1 (CD2BP1) are located in P2 and P4 (carboxy-terminal homology (CTH) domain), respectively. The carboxyl terminus of Lyp1
contains a consensus motif for cyclin-dependent kinase 1 (CDK1). The exonic and basic domain structure is deduced from Ensembl (Ensembl 64,
Se tember 2011) [30] and UCSC Gen me Browser (GRCh37/hg19 assembly) [31] and publishe articles [3,12].
Table 1 Expression of PTPN22 transcripts in peripheral
blood mononuclear cells from cohorts I, II and III
Median relative quantity values
Control group RA patient group P-valuea
Cohort I n = 44 n = 44
PTPN22_v4 1.05 0.85 0.08
PTPN22-long 1.03 1.20 0.006
long/v4b 1.01 1.42 6 × 10-9
Cohort II n = 19 n = 47
PTPN22_v4 0.98 0.96 0.85
PTPN22-long 0.97 1.07 0.25
long/v4b 0.96 1.15 0.02
Cohort III n = 48 n = 48
PTPN22_v4 0.96 0.72 1.2 × 10-4
PTPN22-long 0.97 0.92 0.2
long/v4b 1.04 1.24 0.01
aP-value for comparison of rheumatoid arthritis (RA) patient group and control
group, Mann-Whitney test. bThe ratio of PTPN22-long and PTPN22_v4 was
calculated for each sample separately.
Ronninger et al. Genome Medicine 2012, 4:2
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the expression of these in IFNg-stimulated PBMCs from
the same healthy individuals and RA patients (cohort I).
We found that the average expression of PTPN22 splice
forms in these samples was similar for RA patients and
controls for PTPN22_v4 and PTPN22-long forms, as
well as for the ratio between the two (Table 2). These
data suggest that proinflammatory conditions, such as
IFNg stimulation, may directly change the transcrip-
tional profile for PTPN22 splice forms and that PBMCs
from healthy individuals are able to produce higher
amounts of PTPN22-long forms.
The influence of major RA risk factors on expression of
PTPN22 splice forms in PBMCs of RA patients
We analyzed the expression data with regard to several
parameters related to the risk of RA or disease activity,
including gender, age at disease onset, rheumatoid factor
(RF) and ACPA status, smoking, the HLA-DRB1 SE,
polymorphisms in the PTPN22 locus, DAS28 at baseline
and type of medication for cohort I.
The HLA-DRB1 SE was found to be moderately asso-
ciated with the expression of PTPN22. As can be seen in
Figure 2, RA patients carrying two copies of the SE had
moderately higher expression of both PTPN22_v4 (P =
0.04) and PTPN22-long forms (P = 0.02) compared to indi-
viduals with no or only one copy. However, the ratio
between expression values of the short and long forms
does not significantly differ in individuals with two copies
of the SE allele in comparison with those with one or no
SE alleles.
The RA risk SNP rs2476601 (PTPN22 R620W) did
not associate with the expression of splice forms in our
study, nor did any other polymorphism in the PTPN22
locus show a consistent association. A list of all tested
SNPs can be found in Table S3 Additional file 2.
Influence of methotrexate on PTPN22 expression
Since most of the RA patients were treated with a spec-
trum of anti-inflammatory drugs and disease-modifying
antirheumatic drugs (DMARDs), we tested how these
influence the expression of PTPN22 mRNA. The direct
effect of pharmacological levels of methotrexate was
investigated in two cell lines and in PBMCs from
healthy donors (Figure 3a,b); as can be seen in the fig-
ures, we found only moderate effects on PTPN22
expression. Additionally, we compared the expression
levels of PTPN22 between RA patients with and without
methotrexate treatment at the time of blood donation
and found no differences (Figure 3c). We also found no
effect of type of other medications on the relative
expression or the ratio of the splice forms (data not
shown).
Expression of PTPN22 splice forms in PBMCs from
multiple sclerosis patients
To control for disease specificity of differential expres-
sion of PTPN22 splice forms, we analyzed independent
collections of mRNA from PBMCs from individuals with
MS. The MS patient group showed significantly higher
expression of PTPN22_v4 compared to the control group
(P = 0.01; same controls and same measurement as for
cohort I) and consequently a lower ratio of splice forms
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Figure 2 Expression of PTPN22 splice forms. (a) The ratio of PTPN22-long forms and PTPN22_v4 for rheumatoid arthritis (RA) patients and
controls in cohort I. (b) Expression of PTPN22_v4 and PTPN22-long forms for RA patients stratified by copies of the shared epitope (SE), 0 or 1
(white boxes) versus 2 (grey boxes). (c) The effect of IFNg ex vivo stimulation on expression ratio.
Table 2 Expression of PTPN22 transcripts in peripheral
blood mononuclear cells from healthy controls and
rheumatoid arthritis patients after stimulation with IFNg
(cohort I)
Median relative quantity values
Control group RA patient group P-valuea
Cohort I
PTPN22_v4 0.71 0.68 NS
PTPN22-long 1.36 1.38 NS
long/v4 1.75 1.87 NS
All values are relative to the average expression of non-induced controls. aP-
value for comparison of the patient group and control group, Mann-Whitney
test. NS, not significant.
Ronninger et al. Genome Medicine 2012, 4:2
http://genomemedicine.com/content/4/1/2
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Figure 3. Expression of PTPN22 splice forms. (a) The ratio of PTPN22-long forms and 
PTPN22_v4 for rheumatoid arthritis (RA) patients and controls in cohort I. (b) Expression of 
PTPN22_v4 and PTPN22-long forms for RA patients stratified by copies of the shared epitope 
(SE), 0 or 1 (white boxes) versus 2 (grey boxes). (c) The effect of IFNγ ex vivo stimulation on 
expression ratio. 
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PTPN22_v4 and PTPN22-long forms (p = 0.04 and p = 0.02, respectively, Mann-Whitney U 
test) compared to individuals with no SE or only one copy (Figure 3b). 
The RA risk SNP rs2476601 (PTPN22 R620W) did not associate with the expression of 
splice forms in our study, nor did any other polymorphism in the PTPN22 locus show a 
consistent association.  
We also tested how relevant inflammatory drugs and disease-modifying antirheumatic drugs 
(DMARDs) influence the expression of PTPN22 mRNA. The direct effect of 
pharmacological levels of methotrexate on PTPN22 expression was investigated in two cell 
lines and in PBMCs from healthy donors, and was found to be moderate. Additionally, we 
compared the expression levels of PTPN22 between RA patients with and without 
methotrexate treatment at the time of blood donation and found no differences.  
To control for disease specificity of differential expression of PTPN22 splice forms, we 
analyzed independent collection of mRNA from PBMCs from individuals with multiple 
sclerosis (MS) and, separately, asthma. The MS patient group showed significantly higher 
expression of PTPN22_v4 compared to the control group and consequently a lower ratio of 
splice forms compared to controls. The asthma group did not show differential expression of 
PTPN22 transcripts when compared to healthy controls. 
Our data show that RA patients and healthy controls differ in terms of expression ratio of 
splice forms derived from the PTPN22 gene. This balance shift does not appear to be caused 
by standard treatment and may be of importance during immune response due to significant 
difference in structural features of the encoded PTPN22 proteins. 
 
6.2 PAPER II: PTPN2 VARIATIONS INTERACT WITH HLA-DRB1 SHARED 
EPITOPE ALLELES AND PTPN2 IS DIFFERENTIALLY EXPRESSED IN 
RHEUMATOID ARTHRITIS 
Different studies have identified PTPN2 as a susceptibility locus associated with RA. The 
Wellcome Trust Case Control Consortium reported an association of the single nucleotide 
polymorphism (SNP) rs2542151, located 5.5 kb downstream of PTPN2 with Crohn’s disease, 
celiac disease and RA (87). The association to RA was reported for SNPs rs1893217, 
rs7234029, and rs62097857, located in the intronic sequence of PTPN2 (36). In addition, the 
intronic SNP rs657555 was associated with RA in a Korean population. Even though 
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multiple SNPs within the PTPN2 region have been discovered, the functional consequences 
of these variations for the pathogenesis of RA remain unclear. 
We identified 11 SNPs available in GWA study in the PTPN2 locus, both in the EIRA and in 
NARAC study. These SNPs were tested for interactions with HLA-­‐‑DRB1 SE using a 
dominant genetic model. For the EIRA study, an additive interaction was observed between 
HLA-­‐‑DRB1 SE and three SNPs in the PTPN2 region regarding risk of developing RA: 
rs2847297, rs657555, and rs11080606 (Figure 4). 
 
The PTPN2 SNP rs657555 was additionally tested for interaction with HLA-­‐‑DRB1 SE 
alleles in the extended EIRA study (2019 ACPA positive RA cases, 1126 ACPA negative RA 
cases, and 2247 healthy controls). We found that this SNP was in interaction with HLA-­‐‑
DRB1 SE in ACPA positive RA in extended cohort too. 
For the NARAC study, interaction was observed between HLA-­‐‑DRB1 SE and three SNPs in 
the PTPN2 region: rs1893217, rs657555, and rs11080606. These results leave PTPN2 SNPs 
rs657555 and rs11080606 as most reliable candidates for interaction with HLA-­‐‑DRB1 SE 
regarding risk of developing of ACPA positive RA in EIRA and NARAC studies. Our 
analysis revealed a significant association of PTPN2 SNP rs657555 with RA in EIRA while 
rs11080606 was not associated with the disease.  
We measured the expression levels of total PTPN2 and, separately, the transcripts TC41, 
TC45, and TC48, relative to expression of the reference house-­‐‑keeping gene ZNF592 in 
whole blood and PBMCs of RA patients and healthy controls. We found, however, that TC41 
mRNA was not expressed at detectable levels in whole blood samples and PBMCs. In whole 
blood samples (67 RA patients and 70 healthy controls), we found no differences in average 
expression of total PTPN2 and TC45 between healthy controls and RA patients. However, we 
found marginally lower average expression of TC48 in RA patients (p = 0.046) and also the 
ratio of expression between TC45 and TC48 was significantly different between healthy 
controls and RA patients.  
To identify more specifically the source of differential expression, we also tested the PTPN2 
expression pattern in an independent set of samples from RA patients and controls with 
mRNA extracted from PBMCs. We found a significant difference in expression of total 
PTPN2 and TC48 in healthy controls and RA patients with a higher average expression of 
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total PTPN2 and TC48 observed in RA patients. We detected no difference in TC45 
expression in PBMCs between the groups of healthy controls and RA patients. 
In whole blood samples, we detected no differences in PTPN2 expression with regard to 
HLA-­‐‑DRB1 SE alleles and ACPA status. In PBMCs, we found that the mRNA expression 
levels of total PTPN2 and PTPN2 transcripts are not different in carriers and non-­‐‑carriers of 
HLA-­‐‑DRB1 SE alleles, neither in the control group nor in the RA group. We observed a 
trend in difference between total PTPN2 expression between groups of individuals with 
ACPA positive and ACPA negative RA, however not in PBMCs. 
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Figure 4. Interaction between PTPN2 SNPs and HLA---­‐‑DRB1 SE alleles. Unadjusted P-­‐‑values (-log10) for 
interaction (AP) between HLA - DRB1 SE and the different SNPs in the PTPN2 region of the EIRA (triangle) 
and NARAC (solid circle) cohort plotted against the genomic positions of each SNP on chromosome 18. The 
dominant genetic model was used for the interaction studies. The horizontal dashed line corresponding to a 
threshold of P < 0.05. The LD - plot (r2) is shown for variants in the PTPN2 region. 
 
!
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6.3 PAPER III: GENE-GENE INTERACTION AND RNA SPLICING PROFILES 
OF MAP2K4 GENE IN RHEUMATOID ARTHRITIS 
One of the recent developments in the biological therapy for RA is targeting mitogen-
activated protein kinases (MAPKs), in particular p38 and JNK. MAPKs are considered to be 
among the key inflammatory mediators for autoimmune diseases due to their involvement in 
the regulation of immune response to stress stimuli. MAPK signaling plays a major role in 
proliferation and differentiation of T- and B- cells, which are known to be fundamental in the 
development of autoimmune reaction and sustained inflammatory response. Attempts to 
inhibit the activity of p38 and JNK to treat RA patients in clinical trials were unsuccessful, 
because of unacceptable level of side effects. It has been suggested, that upstream  (MAPKKs 
and MAPKKKs) are responsible for fine regulation of JNK and p38 activity, and may be 
functionally and clinically relevant for RA development. 
We performed interaction analysis on pairwise combinations of HLA-DRB1 SE alleles and 
195 SNPs from 12 genetic loci encoding known MAP2K, MAP3K and MAP4K upstream of 
JNK1 and p38 (including JNK1), in 1921 RA cases and 1079 healthy controls (EIRA cohort). 
Our data indicate that a single SNP, rs10468473, is in a relatively strong interaction with 
HLA-DRB1 SE alleles in the development of ACPA-positive RA (AP = 0.79, p = 4.4 x 10−6, 
95% CI [0.51–1.0]).  
To improve the representation of the individuals, positive exclusively for rs10468473 risk 
allele in our interaction analysis, we performed additional genotyping for this SNP in 861 RA 
patients and 1200 controls from EIRA study (not previously included in GWAS). In the 
extended cohort, rs10468473 from the MAP2K4 locus remained in significant interaction 
with HLA-DRB1 SE alleles (AP = 0.434, p = 0.041, 95% CI [0.018–0.85]) (Figure 5). 
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To find possible mechanisms, explaining the risk association of genetic variation in the 
MAP2K4 locus, we investigated the allelic expression of the MAP2K4 gene in mRNA from 
PBMCs of 44 RA patients and 44 matched controls with known rs10468473 genotype. Our 
data showed significantly elevated MAP2K4 expression in RA patients heterozygous for 
rs10468473, compared to individuals homozygous for A allele (p = 0.045; Mann–Whitney U 
test)  (Figure 6a). 
SE alleles in the development of ACPA-positive RA (AP = 0.79,
p = 4.4 × 10−6, 95% CI [0.51–1.0]) (Supplementary Fig. S1,
Supplementary Datasheet SD1).We found little evidence for the
interaction of HLA-DRB1 SE alleles with other genetic variations
in MAP2K and MAP3K related loci, after correction for multiple
comparisons had been performed. The SNP rs10468473 A/G is
located 21 kb downstream of the MAP2K4 gene, with minor
allelic frequency of 0.097 in our healthy control population
(HapMap-CEU MAF 0.093).
To improve the representation of the individuals, positive
exclusively for rs10468473 risk allele in our interaction analysis,
we performed additional genotyping for this SNP in 861 RA
patients and 1200 controls from EIRA study (not previously
included in GWAS). In the extended cohort, rs10468473 from
the MAP2K4 locus remained in significant interaction with SE
(AP = 0.434, p = 0.041, 95% CI [0.018–0.85]) (Fig. 1). These
results imply that the MAP2K4 polymorphism and SE alleles are
associated with a non-linear increase in risk for ACPA-positive
RA. Additionally, we performed haplotype analysis for all 22
GWAS SNPs from the MAP2K4 locus in our cohort of 1167
Swedish Caucasians, but could not observe a strong linkage of
rs10468473 to other MAP2K4 SNPs (Supplementary Fig. S2).
3.2. Association of rs10468473 genotype with
MAP2K4 expression
To find possible mechanisms, explaining the risk association
of genetic variation in the MAP2K4 locus, we investigated
the allelic expression of the MAP2K4 gene in mRNA from
peripheral blood mononuclear cells of 44 RA patients and 44
matched controls with known rs10468473 genotype. Our
data showed significantly elevated MAP2K4 expression in RA
patients heterozygous for rs10468473, compared to individuals
homozygous for A allele (Fig. 2A). This difference in MAP2K4
expression between different rs10468473-genotypes could not
be observed in healthy controls (Fig. 2B). Due to the low
frequency of theminor allele, individuals with the homozygotic
state of the G were not present in our expression panel.
3.3. MAP2K4 gene is expressed as alternative
putatively protein-coding transcripts
We performed an exploratory study by using generic PCR to
identify a spectrum of MAP2K4 mRNA products, detectable in
PBMC.We identified a series of transcripts with altered exonic
composition, and a prevalence of “cassette-exon”-type
splicing events in the coding part of the Serine/Threonine
protein kinase catalytic domain (Fig. 3A) Specifically, exon 5
skipping had been reported previously for various transcripts
of human (ENST00000538465; ENST00000538465) and mouse
(ENSMUST00000125598) origin, and was featured in our mate-
rial (Fig. 3B). In a screening in mRNA from the PBMC, we could
observe and sequence transcripts with exon 5 skipping in mRNA
from 19/20 RA patients and 20/20 controls (Supplementary
Fig. S3).
Importantly, the absence of exon 5 alone does not result
in a shift of open reading frame. To assess the possibility of
translation forMAP2K4 transcript with skipped exon 5 (assigned
as V2), we transfected HEK293 cells with V1- and V2-containing
plasmids. Both V1 and V2 transfection products could be
detected by using commercially available mouse monoclonal
anti-MAP2K4 in lysates of transfected HEK293 cells. Proteins
with similar molecular weight were also detectable in non-
transfected T-lymphocyte cell lines by Western Blot, using
commercially available mouse monoclonal anti-MAP2K4 against
the C-terminal part of MAP2K4 (Fig. 3C).
3.4. Differential expression of MAP2K4 transcripts
reflects genetic and phenotypic features of RA
We investigated the production of MAP2K4 transcript with
skipped exon 5 (assigned as MAP2K4_V2) in relation to the
expression of canonic full isoform (assigned as MAP2K4_V1),
in PBMC from 38 RA cases and 43 controls, using probe-based
RT-qPCR with probes spanning exonic junctions 4/5 and 4/6,
respectively. When taken as a ratio (V2/V1), the expression
Figure 1 SNP rs10468473 from the MAP2K4 locus, when combined with SE, provides a significant, non-additive increase in risk for
ACPA-positive RA. Representative data shown for extended EIRA cohort. The statistical interaction is represented by attributable
proportion (AP). The analysis was based on 2010 ACPA-positive cases and 2280 healthy controls. Data presented as relative risk (RR)
for carriers of different risk genotypes: SE — individuals with shared epitope risk genotype; rs10468473 — individuals with MAP2K4 rs
10468473_A risk genotype; −rs10468473_A + SE— individuals with bothMAP2K4 rs1046847 and SE risk genotypes; reference line (dashed)—
unaffected individuals; the area of the squares represents the log-size of the genotype group; whiskers show RR confidence intervals.
22 K. Shchetynsky et al.
Figure 5. SNP rs10468473 from the MAP2K4 locus, when combined with SE, provides a 
significant, non-additive increase in risk for ACPA-positive RA. The statistical interaction is 
represented by attributable proportion (AP). The analysis was based on 2010 ACPA-positive 
cases and 2280 healthy controls. The unaffected reference group included 11 individuals. Data 
presented as relative risk (RR) for carriers of different risk genotypes: SE — individuals with 
shared epitope risk genotype; rs10468473 — individuals with MAP2K4 rs 10468473_A risk 
genotype; − rs10468473_A + SE — individuals with both MAP2K4 rs1046847 and SE risk 
genotypes; reference line (dashed) — unaffected individuals; the area of the squares represents 
the log-size of the genotype group; whiskers show RR confidence intervals. 
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We performed an exploratory study by using generic PCR to identify a spectrum of MAP2K4 
mRNA products, detectable in PBMC. We identified a series of transcripts with altered 
exonic composition, and a prevalence of “cassette-exon”-type splicing events in the coding 
part of the Serine/Threonine protein kinase catalytic domain. Specifically, exon 5 skipping 
had been reported previously for various transcripts of human (ENST00000538465; 
ENST00000538465) and mouse (ENSMUST00000125598) origin, and was featured in our 
material (Figure 7a).  
To assess the possibility of translation for MAP2K4 transcript with skipped exon 5 (assigned 
as V2), we transfected HEK293 cells with canonical MAP2K4 sequence (V1) and V2-
containing plasmids. Both V1 and V2 transfection products could be detected by using 
commercially available mouse monoclonal anti-MAP2K4 anti-bodies in lysates of transfected 
HEK293 cells. Proteins with similar molecular weight were also detectable in non-transfected 
T-lymphocyte cell lines by Western blot (Figure 7b). 
Figure 6. rs10468473 genotype correlates with MAP2K4 gene expression in RA patients. (a) The 
expression of MAP2K4 gene is significantly higher in PBMC of 13 RA patients, with a heterozygous G/A 
genotype for rs10468473, compared to 22 patients homozygous for A allele (p = 0.045). (b) In healthy 
controls, no significant change in MAP2K4 expression was observed between individuals with G/A (n = 4) and 
A/A (n = 32) rs10468473 genotypes. Shown are the relative quantification values (RQ) for MAP2K4 
expression in PBMCs of RA patients and healthy controls with known rs10468473 genotype. The expression 
of MAP2K4 was measured by TaqMan qPCR using predesigned gene-expression assay Hs00387426_m1, 
spanning exons 3–4 of the original sequence. Mann–Whitney U test with a significance threshold of p = 0.05 
was used for statistical analysis. 
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We investigated the production of MAP2K4 transcript with skipped exon 5 (assigned as 
MAP2K4_V2) in relation to the expression of canonic full isoform (assigned as 
MAP2K4_V1), in PBMC from 38 RA cases and 43 controls. When taken as a ratio (V2/V1), 
the expression of the transcripts was significantly different for RA patient and healthy control 
groups.  
 
 
 
In RA patients, we identified a significant correlation and a dosage effect between the number 
of carried SE alleles and the MAP2K4 V2/V1 expression ratio. Within the same group, we 
could also observe a correlation between the MAP2K4 variant expression ratio and RA-
related serological factors, i.e. the presence of ACPA and presence of rheumatoid factor.  
initially observed in the EIRA cohort that was later substantially
extended with additional rs10468473 genotyping data. These
results constitute an interaction profile that is connected to
increased risk of ACPA-positive rheumatoid arthritis and can be
helpful for clinical prediction in the future. Based on the
interaction of MAP2K4 SNP with the major risk factor for RA, it
is possible thatMAP2K4 plays a role in RA pathogenesis only in a
specific subgroup of individuals with HLA-DRB1 SE alleles.
Notably, rs10468473 MAF is higher in Asian populations than in
Caucasians. It would be interesting to investigate found effects
in relation to RA in these populations.
Importantly, we observed association of the rs10468473
genotype with MAP2K4 mRNA expression, in our material of
PBMC from RA patients. This allows us to assume that
rs10468473, or other SNPs in high linkage disequilibrium (LD)
with it, is potentially related to the regulation of expression in
the MAP2K4 locus, and could be involved in inflammatory
responses in RA.
To achieve the required variety of functions, almost all
immunologically relevant genes undergo alternative splicing
[17]. It has been suggested that the balance in production of
alternatively-spliced gene transcripts could be relevant for
disease progression and, hence, for the development of
potential therapies [18]. Additionally, the isoforms of proteins
with a function in immunity, such as CD44, TNFR2, IL-32, and
IL-6R, were also shown to influence antigen processing and
have a clinical relevance for autoimmunity [19–22]. Hytönen
A.-M. et al. have demonstrated that a higher level of soluble
IL-4R isoforms in asthma patients, compared with controls,
has biological consequences [23]. It was also demonstrated
Figure 3 Transcript diversity from the MAP2K4 gene. A. The schematic of the MAP2K4 transcripts illustrates structural difference
between the canonical and the alternatively spliced forms, with a black bracket over the amplification area. Exons 3–11 form the
translated catalytic domain of MAP2K4 protein (gray rectangle). Exon junctions targeted with custom TaqMan probes MAP2K4_v1 and
MAP2K4_v2 are marked with black and gray asterisks respectively. “†” marks position of the TaqMan probe in commercial assay
Hs00387426_m1. B. A “skipped-exon” variant MAP2K4 was characterized in whole-blood mRNA. Shown are the PCR amplification
spanning exons 3–11 of the original MAP2K4 sequence. The canonical MAP2K4 transcript (black arrow) and a “skipped exon” splice
form (gray arrow) were confirmed through sequencing. C. MAP2K4 NoE5 protein isoform can be detected with monoclonal
anti-MAP2K4 G6 and rabbit polyclonal G6 IgGs in lysates of in HEK293 cells, transfected with cDNA of NoE5 splicing variant of MAP2K4.
The produced band is similar to the lower molecular weight product in 2-product pattern, detectable with the same antibody in both
HEK293 cells, transfected with canonical MAP2K4 cDNA and untransfected Jurkat cells (right). Full-MAP2K4-transfected and
untransfected HEK293 also exhibit lower molecular weight products that are not present in the MAP2K4 NoE5 HEK293 transfection.
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Figure 7. MAP2K4 transcript, lacking exon 5 may undergo translation into protein  
(a) A “skipped-exon” variant MAP2K4 was characterized in whole-blood mRNA. Shown are the 
PCR amplification spanning exons 3–11 of the original MAP2K4 sequence. The canonical 
MAP2K4 transc ipt (black a row) and a “skipped exon” splice f rm (gray arrow) were c nfirmed 
through sequencing. (b) MAP2K4 NoE5 protein isoform can be detected with monoclonal anti-
MAP2K4 G6 and rabbit polyclonal G6 IgGs in lysates of in HEK293 cells, transfected with cDNA 
of NoE5 splicing variant of MAP2K4. The roduced band is similar to the lower molecular weight 
product in 2-product pattern, detectable with the same antibody in both HEK293 cells, transfected 
with canonical MAP2K4 cDNA and untransfected Jurkat cells (right). Full-MAP2K4-transfected 
and untransfec ed HEK293 also exhibit low r molecular weight pro ucts that are not present in the 
MAP2K4 NoE5 HEK293 transfection. 
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We studied the effect of TNF stimulation on the transcript expression ratio of MAP2K4 in 
lymphatic and myeloid cell-lines. The expression of MAP2K4 V1/V2 was measured at four 
different time points in Jurkat, Raji, and U937 cell lines treated with recombinant TNF. The 
transcripts of MAP2K4 were differentially expressed in T-cell-like Jurkat cell-line at 24 h of 
stimulation. There was no significant difference in transcript ratio for Raji and U937. 
Our data suggest a presence of the genetic interaction between MAP2K4 and HLA-DRB1, 
and the importance of rs10468473 and MAP2K4 splice variants in the development of 
autoantibody-positive RA. 
6.4 PAPER IV: EXPRESSION PATHWAY ANALYSIS FOR GENES 
ASSOCIATED WITH RHEUMATOID ARTHRITIS 
The rapid decline in cost of RNA-sequencing, combined with a dramatic increase in 
throughput turned into an indispensible tool for transcriptome research. 
However, there are multiple ways of data analysis for RNA-seq derived results, but little 
consensus about a unified analysis and interpretation approach. Integration of multiple RNA-
seq data with immense amounts of data from GWAS studies, and protein interaction 
databases may ameliorate the interpretation program, and contribute to the discovery of new 
molecular targets, supported on multiple levels of experimental evidence. Importantly, 
integration with whole-transcriptome analysis methods allows for a more informative view of 
candidate gene expression, as expression of multiple transcripts from different loci can be 
assessed in a single experiment.  
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Figure 8. Out of the initial set of genes	  in	  direct	  proximity	  to	  reported	  RA	  variants,	  those	  DE	  in	  our	  RNA-­‐seq	   data	  were	  used	   in	   Ingenuity	   Pathway	   analysis	   sofware.	   Interaction	  molecules,	   suggested	   by	   IPA	  were	  again	  compared	  to	  the	  RNA-­‐seq	  differential	  expression	  results. 
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The general design of the study is presented in Figure 8. Candidate genes were chosen based 
on proximity to validated genetic variants. RNA-seq was performed on whole-blood samples 
of 12 healthy controls, 6 RA patients before methotrexate treatment, and 6 RA patients 
undergoing methotrexate treatment (all individuals were of female sex). The consideration 
that treatment may have a pronounced effect gene expression informed our selection of 
differentially expressed genes – only genes with similar expression in treated and untreated 
RA patients were selected. Out of 108 genes from RA-associated loci (4, 103, 139-142), 28 
genes remained differentially expressed by RNA-seq between any of the three groups after 
correction, but only 10 were differentially expressed in both non-treated RA and treated RA 
compared to healthy controls (p=0.05, Fisher combined p-value). As expected, clustering 
based on the expression pattern of these 10 genes results in reasonably good separation of 
healthy controls and RA patients, but does not provide a clear distinction for the treatment 
status. 
!
*!
Figure 9. A network, containing HLA-DRB1 and 9 other genes, significantly DE in whole blood 
RNA-seq data (Ingenuity Pathway Analysis (IPA)). Gray shapes represent genes, previously associated 
in RA, that are also DE in RNA-seq data (IPA-­‐‑input), White shapes represent interaction molecules, 
derived from IPA database; solid lines – direct interaction evidence; dashed lines – indirect interaction 
evidence; asterisk - significant difference in expression in whole blood from both naïve RA vs. HC and 
treated RA vs. HC RNA-seq data comparisons. 
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With the use of IPA software, 10 differentially expressed genes were grouped into a 
functional molecular network with an IPA score of 12, involving 29 additional interacting 
molecules, based on experimental data from immune cells and cell lines (Figure 9).  
HLA-DRB1, HSPB1 and ERBB2 retained a significant DE profile in both untreated and 
treated RA compared to healthy controls after multiple testing correction of the combined p-
values from both comparisons (data for ERBB2 presented at Figure 10a). 
To replicate our findings we employed analysis of RNA-seq data from independent cohort of 
PBMCs from 48 untreated female RA patients, 30 methotrexate treated RA female patients, 
and 35 healthy female controls. ERBB2 expression remained significantly different in PBMC 
samples, with the gene expression pattern similar to that, observed in whole blood, and a 
significant difference in expression between healthy controls and untreated patients (Figure 
10b).  
In this study, an integration of RNA-seq data with prior association study data and with 
following pathway analysis allowed us to infer new candidate genes and molecular pathways 
that are potentially involved in RA pathogenesis. Integrated pathway analysis implies a 
potential functional link between several genes previously associated with RA, and new 
candidates, ERBB2 and HSPB1. 
Figure 10. (a) ERB22 was significantly DE in whole blood from 6 pre-treatment RA patients and 12 healthy 
controls (p=0.029), and a trend towards DE in treated RA patients and 12 healthy controls (p=0.086); 
Bonferroni corrected Cuffdiff p---­‐‑value of 0.05 was used as threshold. (b) The DE of ERBB2 was replicated 
in PBMCs samples from an independent cohort of 48 untreated RA patients, 30 methotrexate treated RA 
patients, and 35 healthy controls (p=0.033). Mann Whitney test p-value of 0.05 was used as a significance 
threshold. 
HC – healthy controls: nRA – “naïve” RA patients: tRA – treated RA patients; 
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7 DISCUSSION 
 
7.1 OVERVIEW 
From the era of the GWAS studies, we have discovered multiple genetic variants associated 
with disease. In genetic studies, association allows us to attribute a degree of causation to 
genetic variance, due to the role of the genome as a basis for structure and function of a 
biological system. However, association remains a purely statistical concept that does not 
provide us with enough information to infer the function of a particular genetic variant.  
In case of RA, great progress has been made in pinning down the genetic variance that could 
contribute to disease development. However, the understanding of how this genetic 
contribution is realized is far from complete.  
Assessing the functional importance of a given genetic variant includes a vast set of methods, 
spanning from bioinformatics and gene expression analysis to proteomics and genetically 
modified model organisms.  
The intention of thesis work was to fill the gaps in our understanding of the genetic events 
that form the genetic component of RA. Specifically, a number of loci associated with RA 
were studied in terms of their expression, splicing profile and interaction with HLA-DRB1. 
To achieve this, we resorted to a combination of distinct methodological approaches, 
discussed below. 
Gene-gene interaction analysis can be a useful tool to get a glimpse of the potential functional 
connections between associated loci, while using available GWAS data. It allows for 
identification of genetic associations, which are otherwise missed due to methodological 
constraints of GWAS. Interaction analysis enabled us to report a novel associated 
polymorphism in PTPN2 gene, which we initially detected through interaction with HLA-
DRB1. Furthermore, our work on MAP2K4 was also prompted by a gene-gene interaction 
analysis of the members of MAPK signaling pathway with HLA-DRB1. 
The measurement of total gene expression for candidate genes has been a routine approach 
testing the functional involvement of a genetic locus in disease pathogenesis. However, with 
our current understanding of the complexity of the transcriptome, this approach may no 
longer be sufficient. Detection methods, relying on a consensus part of the transcripts, will 
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not yield complete information in cases, when alternative mRNA splice forms of a gene are 
differentially regulated. In our work on PTPN22 and PTPN2, we try to circumvent this issue, 
by differentiating between the existing isoforms of these genes in our expression studies. 
Further more, in the study MAP2K4 we include transcript discovery stage to create a detailed 
picture of the gene expression profile, prior to expression analysis in clinical samples and cell 
lines.  
Lastly, to find new functionally relevant candidates in RA we required an approach that 
would integrate validated susceptibility loci from GWAS, gene expression genome-wide 
profiling, and existing experimental evidences. This prompted us to take advantage of the 
increased efficiency and availability of RNA-seq technology, which was used to analyze 
mRNA expression for genes, proximal to verified susceptibility loci for RA, in clinical 
samples from RA patients and healthy individuals. We used pathway analysis to look for 
existing evidence of the possible functional interactions for genes that are both proximal to 
RA-associated variants and differentially expressed in case-control expression study. We 
proceeded to investigate the expression of the functionally relevant genes, suggested by 
pathway analysis. 
 
7.2 EXPRESSION PROFILES OF PTPN22 AND PTPN2 IN RA 
The polymorphisms from genes PTPN22 and PTPN2 were previously found in association 
with RA, with PTPN22 being second strongest risk factor for the disease. Both genes belong 
to the family of protein tyrosine phosphatases.  
PTPN22 SNP rs2476601 was previously reported to be in interaction with HLA-DRB1 SE in 
determining the risk of RA. Therefore, it was interesting to also see an association of PTPN22 
expression to HLA-DRB1. 
Notably, PTPN22 protein isoforms, corresponding to the transcripts in this study, have 
distinct structural differences, reported previously. For instance, not all functional motifs, 
common between Lyp1 and other members of the PEST family of phosphatases, PTP-PEST 
(PTP with PEST domain, genomic designation PTPN12) and PTP-HSCF (PTP hematopoietic 
stem-cell fraction, genomic designation PTPN18) are preserved in Lyp 2. These differences 
include the absence of the carboxy-terminal homology (CTH) domain, which is a binding site 
for CD2-binding protein 1 (CD2BP1), cyclin-dependent kinase 1 (CDK1) recognition motif, 
and 2 out of 3 SRC kinase binding sites. 
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These differences could very well stand behind the association of PTPN22 with the RA 
phenotype. For example, CD2BP1 is expressed in T cells and has been proposed to be an 
important regulator of T-cell behavior by modulating CD2 activity, which in turn regulates 
the binding of T-cell receptors to a major histocompatibility complex (MHC) molecule with 
an antigenic peptide. Cyclin-dependent kinase 1 (CDK1), a cell cycle regulatory kinase, 
which may imply a difference in cell-cycle dependent regulation of Lyp2 regulation 
compared to Lyp1 (138). c-Src is known to negatively regulate leukocyte-specific protein 
tyrosine kinase - an important mediator in cytokine production signaling. 
 
These possible functional differences between Lyp1 and Lyp2 were not appreciated 
previously and may suggest that a shift in the balance of splice forms could have a 
considerable impact on the inflammatory signaling. This difference in expression seems not 
to be significantly regulated by allelic variants and although it cannot be totally excluded 
according to our cell line experiments, the expression seems not to be affected by medication 
of the patients. Also, in the presence of a strong inflammatory environment (IFNγ in our 
study) the balance in transcript expression could be well compensated. Interestingly, our 
study of PTPN22 splice form expression in MS patients did not show a similar effect, which 
is in line with the fact that this disease is not associated with polymorphisms in the PTPN22 
gene and supports disease specificity. To resolve if this difference in expression is related to 
genetic association with PTPN22 variants, expression of PTPN22 splice forms in systemic 
lupus erythematosus and type 1 diabetes, diseases shown to be associated with variations in 
PTPN22, should be tested in a similar way. 
 
In the present study, we were able to identify an additional susceptibility SNP in PTPN2 that 
distinguish a subgroup of RA cases from healthy controls, through the analysis of interactions 
between SNPs in PTPN2 and HLA-DRB1 SE. Although the size of the subgroup is moderate, 
the effect of this combination on RA risk is relatively high. 
 
Evidence of interaction between the PTPN2 SNP rs657555 and HLA-DRB1 SE was 
observed in both the EIRA and NARAC study for ACPA positive disease, when an additive 
model was used. In addition, our analysis revealed a significant association of rs657555 with 
RA. A possible biological background for the interaction between HLA-DRB1 SE and 
PTPN2 might be that PTPN2 regulates T-cell receptor signaling. However, the potential link 
between PTPN2 and HLA-DRB1 SE should be further investigated in functional studies in 
relation to different autoimmune diseases.  
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There was no experimentally determined proof that the PTPN2 SNP rs657555 had any 
regulatory features. In addition, we found that rs657555 does not correlate with the 
expression of total PTPN2, TC45, and TC48 mRNA levels in whole blood samples and 
PBMCs of healthy controls and RA patients. Given that rs657555 is in strong LD (r2 > 0.8) 
with 20 intronic SNPs, it can be hypothesized that one of these SNPs is the actual causal 
variant. We investigated the 20 intronic SNPs in PTPN2 using the databases HaploReg and 
RegulomeDB and discovered that rs7241016 and rs11875687 are likely to affect the binding 
of STAT1 and/or STAT3, which might in turn regulate the expression of genes after cytokine 
or growth factor stimulation. The SNP rs534911 may affect the binding of CTCF, which is a 
crucial regulator of transcription and may also influence mRNA splicing. Because these 
SNPs might have regulatory features, they provide candidates for future investigation.  
 
The current study also detected that average levels of total PTPN2 and TC48 expression are 
significantly higher in PBMCs of healthy controls and RA patients. The opposite results for 
TC48 expression in whole blood samples and PBMCs of RA patients might be explained by 
the differences in cell composition between whole blood and PBMCs. It will be of interest to 
study the expression of PTPN2 transcripts in specific types of blood cells to reveal the 
function of PTPN2 in RA.  
 
TC45 and TC48 are expressed in different cellular compartments and interact with different 
cellular targets. Many of the TC48-interacting proteins are involved in intracellular vesicle 
transport and cell adhesion. However, further investigation is needed to elucidate the role of 
TC48 in the pathogenesis of RA.   
 
7.3 RELEVANCE OF MAP2K4 GENE IN RA 
Analysis of genetic variations in MAPKK and MAPKKK related loci imply an interaction 
between a single member of the MAP signaling pathway, MAP2K4, and HLA-DRB1 SE 
loci, that may contribute to the risk of autoantibody-positive RA that was overlooked in 
GWAS studies. These results constitute that a gene-gene interaction attributes to increased 
risk of ACPA-positive rheumatoid arthritis and can be helpful for clinical prediction in the 
future. Based on the interaction of MAP2K4 SNP with the major risk factor for RA, it is 
possible that MAP2K4 plays a role in RA pathogenesis only in a specific subgroup of 
individuals with HLA-DRB1 SE alleles.  
 46 
Importantly, we observed association of the rs10468473 genotype with MAP2K4 mRNA 
expression in our material of PBMC from RA patients. This allows us to assume that 
rs10468473, or other SNPs in LD with it, is potentially related to the regulation of expression 
in the MAP2K4 locus, and could be involved in inflammatory responses in RA. 
 
In this study we characterized splicing events in MAP2K4, resulting in partial lack of 
catalytic domain coding sequence. Specifically, MAP2K4_V2, characterized by the skipping 
of exon 5, could be effectively translated into a protein product, as confirmed by our 
transfection experiments could be consistently identified with a specific primer-set in mRNA 
from PBMC of RA patients and controls. The functional implications from the lack of 
catalytic part of MAP2K4 could be substantial: while not crucial for activation of either p38 
or JNK, MAP2K4 works in tandem with MKK6/3 and MKK7, ensuring optimal activation of 
these MAPKs (108). An inadequate upstream regulation of p38 and JNK may influence their 
role as transducers of inflammation and joint destruction. Furthermore, altered regulation of 
JNK could potentially have an effect on the expression of genes, involved in antigen 
presentation (HLA class II and CIITA) (143). 
Additionally, our results show differential expression of the canonical and alternatively 
spliced MAP2K4 mRNAs in RA patients, compared to healthy controls. It also depends on 
ACPA status, RF positivity, and number of SE alleles. The decreased V2/V1 ratio in RA 
patients could be chiefly attributed to the increased expression of canonical MAP2K4 
transcript, while the correlations with SE alleles and serological markers within the RA group 
are driven by V2 (NoE5). 
It has been reported that SNPs located in untranslated areas may contribute to the regulation 
of gene splicing (144). However, we could not see a clear association between the 
rs10468473 or 21 other common MAP2K4 SNP genotypes with the expression of individual 
splicing variants (canonical and lacking exon 5) of the MAP2K4 gene.  
 
TNF signaling leads to the activation of JNK, p38 and ERK MAPKs (111, 145). The 
observed effect of TNF stimulation on the transcript ratio in our experiments in the Jurkat 
cell-line, but not in Raji or U937, may indicate a cell-type specific splicing profile of 
MAP2K4 in pro-inflammatory conditions — and a topic for further analyses of mechanisms 
of involvement in RA and development of treatment strategy. This is in line with the 
established effect of anti-TNF treatment in RA and suggests how T-cell specific expression 
of MAP2K4 isoforms could be functionally involved in RA pathogenesis through the 
regulation of proliferation in the T-cell population. 
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Alternative mRNA transcripts can have a regulatory function by competing with the 
canonical transcript and shifting the amount of the main variant in the total gene output. This 
knowledge can support the functional significance of splicing in MAP2K4 transcripts, even 
when the translation efficiency for non-canonical products is lower. It also seems reasonable 
to consider the possibility of NMD-subjected transcripts potentially retaining mRNA-level 
regulatory capacity in disease pathogenesis. It remains to be determined whether, and if so, 
how the balance of MAP2K4 splice variants may functionally affect the activation of 
downstream JNK and p38 in the context of autoimmunity. The quantity of an alternative 
MAP2K4 isoform could potentially interfere with complex formation and activation of 
downstream p38 and JNK MAPKs. If the gene expression of MAP2K4 is constitutively 
effected by a specific genotype it could potentially contribute to the development of 
autoimmunity over time.  
 
7.4 108 RA ASSOCIATED LOCI: EXPRESSION AND PATHWAY ANALYSIS 
Genetic association and gene-gene interaction studies were instrumental in detection of 
important candidate genes in the development of RA. However, it may show only a reflection 
of possible functional involvement of genomic mechanisms and alternative approaches, like 
study of gene expression are important. However, despite the decrease in the cost of RNA-
seq, we have a limitation in the number of samples for the analysis with relatively low 
statistical power for genome-wide comparison. To address potentially unknown disease 
associated pathways, we integrated validated GWAS markers with whole transcriptome 
expression data and pathways analysis thus limiting our selection to well validated genetic 
risk factors with the goal to link it with other members of the disease pathways. 
We identified that 10 of the genes, proximal to validated RA-associated variance, were 
differentially expressed in our material of whole blood samples from 12 RA patients and 12 
healthy controls. Notably, samples could be reasonably grouped into RA and non-RA based 
on this expression profile alone. This particular gene set, however, does not provide a 
distinctive clustering between treated and untreated RA patients. This circumstance aligns 
with our intention to avoid genes, displaying heterogeneity of expression of genes depending 
on response to treatment.  
 
Using the Ingenuity Pathway Analysis service, we obtained information about the functional 
interactions for the DE genes from RA-associated loci in primary immune cells and immune 
cell-lines, based exclusively on available experimental data (i.e. the prediction features of the 
software were not employed).  As a result, 6 out of 10 input genes were grouped into a single 
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network, where IL2, IL10 and TNF served as connecting hubs. Importantly, this suggested 
network also contained HLA-DRB1 – the major genetic risk factor of rheumatoid arthritis, 
which was not manually included within the input genes dataset.  
 
Addressing the expression of 28 new “connector” genes, suggested by the pathway analysis, 
revealed that some of them were DE in whole blood from 6 untreated, 6 treated RA patients 
and 12 healthy controls. However, with the exception of HLA-DRB1, ERBB2, and HSPB1 
DE was limited to the comparison of healthy individuals to either treated or untreated RA 
groups, but not both. Notably, replicating ERBB2 expression in an independent material of 
PBMC samples from methotrexate treated and naive RA patients versus healthy controls 
revealed a similar expression pattern, and a significant difference in expression between the 
latter two groups. 
ERBB2 (HER2/neu) is a receptor tyrosine-protein kinase erbB-2, previously implicated in 
promoting hyperproliferative growth in arthritic synovial tissue (146). ERB22 protein was 
shown to be highly expressed in synovial joint(147). However, the ERBB2 expression has 
not been studied before in either whole blood or PBMCs in context of RA. Notably, it is 
known that ERBB2 plays an important role in the activation of the NFkB pathway and, 
potentially, an important mediator of TNF signaling (148, 149), which are both strongly 
implicated in RA pathogenesis. Therefore, assessing the effects of existing ERBB2 inhibitors 
in an experimental model of RA may be a promising endeavor.  
Integration of GWAS data, whole-transcriptome RNA-seq analysis with pathway analysis 
may suggest new relevant genes and interaction networks that can be used for functional 
studies. However, one should be careful to avoid potential annotation mismatches when 
integrating data from different sources. Specifically, for highly computational analysis of 
whole-transcriptome data, it is important to consider biases that may be inherent in a specific 
analysis pipeline.  
Additionally, attribution of associated SNPs to proximal genes could be a limiting factor of 
this study, since it does not take into account potential trans-regulatory effects of SNPs on 
gene expression in other loci. 
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8 CONCLUSIONS 
 
With this work we attempted to elucidate the molecular workings behind genetic association 
in rheumatoid arthritis – a common complex autoimmune disease.  In terms of clinical 
significance, genetic epidemiology has now reached a point of diminishing returns from 
genome-wide association studies, with unprecedented cohort sizes utilized to detect 
extremely modest effects on disease risk. Currently, a lot of ongoing work is focused on 
combining different levels of biological knowledge, and breathing new life into available 
GWAS data. In our view, integration of GWAS data, gene-gene interaction studies, gene 
expression profiles, and model cell-systems allows for functionally meaningful interpretation 
of associated variance. 
 
We believe it is essential to account for a specific transcript profile in genes from 
susceptibility loci. Based on our studies of RA associated genes PTPN22 and PTPN2, the 
transcript ratio of a gene may play a role in disease pathogenesis, and reflect other genetic 
and phenotypic features of the disease.   
 
Moreover, as we observed in our work on MAP2K4, it may be important to consider, that the 
functionally relevant alternative splice forms have not yet been reported for the gene of 
interest. 
Gene-gene interaction analysis can be an effective way to utilize GWAS data to find new risk 
variants and functionally associated genes (studies of PTPN2 and MAP2K4, respectively). 
Finally, integration of GWAS data, whole-transcriptome RNA-seq analysis with pathway 
analysis may suggest new relevant genes and interaction networks, that can be used for 
functional studies. 
According to previous studies, genetic risk factors, discussed in this work may participate in 
the pathogenesis of RA on multiple levels (Figure 11). However, more information about the 
functional interplay between HLA-DRB1 and other involved factors is necessary to better 
understand the pathogenesis of RA and, possibly, other autoimmune diseases. We believe, 
this work can be helpful for conducting informed functional studies of genes, involved in RA 
pathogenesis – an essential next step.  
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A common trait of all the studies, included in this thesis, is an attempt to build up from a 
genetic susceptibility variant to a functional gene, relevant to disease pathogenesis, then to a 
protein and its interactions and functions, and, finally, to a signaling network that would help 
us better understand and contain rheumatoid arthritis and other complex autoimmune 
diseases. 
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Figure 11. A schematic of the potential involvement of the discussed genes in the 
pathogenesis of RA and a sustained of autoimmune reaction. APC – antigen presenting 
cell. Solid lines – direct interactions; dashed lines – indirect interactions. 
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